<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="chapter-article"><?DTDIdentifier.IdentifierValue -//Springer-Verlag//DTD A++ V2.4//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName A++V2.4.dtd?><?SourceDTD.Version 2.4?><?ConverterInfo.XSLTName springer2nlmx2.xsl?><?ConverterInfo.Version 1?><?covid-19-tdm?><?noissn?><front><journal-meta><journal-id journal-id-type="publisher-id">978-3-642-15742-4</journal-id><journal-id journal-id-type="doi">10.1007/978-3-642-15742-4</journal-id><journal-id journal-id-type="nlm-ta">Pulmonary Involvement in Patients with Hematological Malignancies</journal-id><journal-title-group><journal-title>Pulmonary Involvement in Patients with Hematological Malignancies</journal-title></journal-title-group><isbn publication-format="print">978-3-642-15741-7</isbn><isbn publication-format="electronic">978-3-642-15742-4</isbn></journal-meta><article-meta><article-id pub-id-type="pmcid">7115022</article-id><article-id pub-id-type="publisher-id">21</article-id><article-id pub-id-type="doi">10.1007/978-3-642-15742-4_21</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Common Viral Pneumonia</article-title></title-group><contrib-group content-type="book editors"><contrib contrib-type="editor"><name><surname>Azoulay</surname><given-names>Elie</given-names></name><address><phone>142499-421</phone><fax>142499-426</fax><email>elie.azoulay@sls.ap-hop-paris.fr</email></address><xref ref-type="aff" rid="AffID1"/></contrib><aff id="AffID1"><institution-wrap><institution-id institution-id-type="GRID">grid.413328.f</institution-id><institution-id institution-id-type="ISNI">0000000123006614</institution-id><institution>Service de R&#x000e9;animation M&#x000e9;dicale, </institution><institution>H&#x000f4;pital Saint Louis, </institution></institution-wrap>Avenue Claude Vellefaux 1, Paris, 75010 France </aff></contrib-group><contrib-group><contrib contrib-type="author"><name><surname>Schnell</surname><given-names>David</given-names></name><xref ref-type="aff" rid="Aff1_21">1_21</xref></contrib><contrib contrib-type="author"><name><surname>Legoff</surname><given-names>J&#x000e9;r&#x000f4;me</given-names></name><xref ref-type="aff" rid="Aff2_21">2_21</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Azoulay</surname><given-names>&#x000c9;lie</given-names></name><address><email>elie.azoulay@sls.aphp.fr</email></address><xref ref-type="aff" rid="Aff3_21">3_21</xref><xref ref-type="aff" rid="Aff4_21">4_21</xref></contrib><aff id="Aff1_21"><label>1_21</label><institution-wrap><institution-id institution-id-type="GRID">grid.7452.4</institution-id><institution-id institution-id-type="ISNI">0000000122170017</institution-id><institution>H&#x000f4;pital Saint Louis, Service de R&#x000e9;animation m&#x000e9;dicale, </institution><institution>Universit&#x000e9; Denis Diderot, </institution></institution-wrap>1 avenue Claude Vellefaux, 75010 Paris Cedex, France </aff><aff id="Aff2_21"><label>2_21</label><institution-wrap><institution-id institution-id-type="GRID">grid.7452.4</institution-id><institution-id institution-id-type="ISNI">0000000122170017</institution-id><institution>H&#x000f4;pital Saint Louis, Laboratoire de Virologie, </institution><institution>Universit&#x000e9; Denis Diderot, </institution></institution-wrap>1 avenue Claude Vellefaux, 75010 Paris Cedex, France </aff><aff id="Aff3_21"><label>3_21</label><institution-wrap><institution-id institution-id-type="GRID">grid.413328.f</institution-id><institution-id institution-id-type="ISNI">0000000123006614</institution-id><institution>Service de R&#x000e9;animation M&#x000e9;dicale, </institution><institution>H&#x000f4;pital Saint-Louis, </institution></institution-wrap>1 avenue Claude Vellefaux, 75010 Paris, France </aff><aff id="Aff4_21"><label>4_21</label><institution-wrap><institution-id institution-id-type="GRID">grid.7452.4</institution-id><institution-id institution-id-type="ISNI">0000000122170017</institution-id><institution>Medical Intensive Care Units, Saint-Louis Hospital, </institution><institution>Paris 7 University, </institution></institution-wrap>Paris, France </aff></contrib-group><pub-date pub-type="epub"><day>19</day><month>8</month><year>2010</year></pub-date><fpage>257</fpage><lpage>273</lpage><permissions><copyright-statement>&#x000a9; Springer-Verlag Berlin Heidelberg 2011</copyright-statement><license><license-p>This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.</license-p></license></permissions><abstract id="Abs1_21"><p>Common respiratory viruses are now recognised as true opportunistic respiratory pathogens in patients with haematological malignancies. The epidemiology of these viruses has not been extensively studied in immunocompromised hosts, but is probably closely related to viral activity in immunocompetent hosts, who constitute the virus reservoir for immunocompromised patients. In these patients, common respiratory viruses may cause severe infections with higher rates of progression to pneumonia and mortality compared to immunocompetent individuals. Prolonged high-titre viral shedding is common in patients with haematological malignancies and may enhance not only viral transmission, but also the selection of resistant strains. Influenza and respiratory syncytial virus (RSV) infections have been particularly well studied. They are associated with pneumonia rates of about one-third for influenza and 30&#x02013;40% for RSV. Both viruses are responsible for mortality rates ranging from 15% to 30%. The exact mechanisms of pneumonia related to these viruses remains unknown, but bacterial and fungal co-infections are frequent and must be carefully investigated. Parainfluenza viruses (PIV) and RSV have also been linked to late airflow obstruction in haematopoietic stem cell transplant recipients. Neuraminidase inhibitor therapy has been suggested for influenza, ribavirin for RSV, and cidofovir for adenovirus infections. However, there is no evidence supporting the use of these drugs, and randomised controlled trials are urgently needed to better define the optimal management of common viral pneumonia in patients with haematological malignancies. The absence of proven effective treatments highlights the critical importance of prevention. Viral transmission may be interrupted by contact isolation with droplet precautions for infected patients and by having patients and health care workers with suspected infection, and their relatives, refrain from visits and work. Immunisation remains the cornerstone of influenza prevention and is recommended for patients with haematological malignancies, their relatives, and health care workers.</p></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Respiratory Syncytial Virus</kwd><kwd>Lower Respiratory Tract Infection</kwd><kwd>Respiratory Syncytial Virus Infection</kwd><kwd>Respiratory Virus</kwd><kwd>Haematopoietic Stem Cell Transplantation</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; Springer-Verlag Berlin Heidelberg 2011</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1_21" sec-type="introduction"><title>Introduction</title><p>Common respiratory viruses are probably among the leading causes of community-acquired pneumonia [<xref ref-type="bibr" rid="CR1_21">1</xref>, <xref ref-type="bibr" rid="CR2_21">2</xref>] but, oddly enough, have long been underrecognised in patients with haematologic malignancies (HMs), perhaps in part due to the lack of rapid and sensitive diagnostic methods and of effective treatments. Over the last 2 decades, the expanding use of high-dose chemotherapy and haematopoietic stem cell transplantation (HSCT) in various malignancies has improved the prognosis of patients with HMs at the cost of increased opportunities for severe infections [<xref ref-type="bibr" rid="CR3_21">3</xref>&#x02013;<xref ref-type="bibr" rid="CR5_21">5</xref>]. Combined with the development of new diagnostic methods and introduction of antiviral drugs, this increased infection rate has rekindled interest in the effects of common respiratory viruses in patients with HMs. These viruses are now recognised as true opportunistic respiratory pathogens in immunocompromised hosts.</p></sec><sec id="Sec2_21"><title>Common Respiratory Viruses</title><p>There is no clear definition of common respiratory virus. Viruses that consistently produce respiratory manifestations are considered respiratory viruses. These include members of the following families of RNA viruses: Orthomyxoviridae (human influenza viruses), Paramyxoviridae (respiratory syncytial virus [RSV], parainfluenza viruses [PIV], and human metapneumoviruses [MPV]), Coronaviridae (human respiratory coronaviruses), and Picornaviridae (human rhinoviruses). Other viruses that cause respiratory manifestations in many, but not all, patients are considered respiratory viruses because they are often associated with seasonal respiratory events. Examples include Adenoviridae (adenoviruses) and some Picornaviridae (non-poliomyelitic enteroviruses). A separate chapter of this book focuses on newly discovered and emerging respiratory viruses (avian influenza viruses, newly discovered coronaviruses, polyomaviruses KI and WU, human bocavirus, and mimivirus). CMV and Herpes pneumonia will also be addressed by Dr. Chemaly and colleagues in two different chapters in this book.</p><p>Human influenza viruses are enveloped, negative-sense, single-stranded RNA viruses. They are classified into three antigenic types, A, B, and C [<xref ref-type="bibr" rid="CR6_21">6</xref>]. The envelope of influenza A and B viruses carries two major antigenic proteins, haemagglutinin (HA) and neuraminidase (NA). HA allows the virus to bind to sialic acid-conjugated glycoproteins at the surface of respiratory epithelium cells. NA plays a crucial role in viral dissemination by releasing newly formed virions from host cells. The influenza C envelope supports a unique protein sharing the properties of both HA and NA and known as haemagglutinin-esterase-fusion factor [<xref ref-type="bibr" rid="CR6_21">6</xref>]. Influenza B and C viruses can infect humans and some mammalian species, whereas influenza A also infects most avian species [<xref ref-type="bibr" rid="CR6_21">6</xref>].<fig id="Fig1_21"><label>Fig. 21.1</label><caption><p>Diffuse alveolo-interstitial pneumonia in a PIV3-infected patient</p></caption><graphic xlink:href="150925_1_En_21_Fig1_HTML" id="MO1_21"/></fig>
</p><p>RSV and PIV types 1&#x02013;4 are enveloped, negative-sense, single-stranded RNA viruses. RSV belongs to the <italic>Paramyxovirus</italic> genus, and PIV 1&#x02013;4 to the <italic>Pneumovirus</italic> genus, of the Paramyxoviridae family [<xref ref-type="bibr" rid="CR7_21">7</xref>]. Their envelopes support two major antigenic surface proteins, one for binding and one for fusion to the cell membrane. Attachment to host cell receptors is mediated by the G protein of RSV and by a haemagglutinin neuraminidase for PIV [<xref ref-type="bibr" rid="CR7_21">7</xref>, <xref ref-type="bibr" rid="CR8_21">8</xref>]. The fusion protein F is common to both genera and allows the virus to penetrate within the host cells after binding [<xref ref-type="bibr" rid="CR8_21">8</xref>]. Antigenic variations in the G protein determine two major RSV groups, A and B. Antigenic variations also occur in PIV but have less immunological impact [<xref ref-type="bibr" rid="CR7_21">7</xref>]. The natural hosts of RSV are humans and chimpanzees, whereas PIV infects only humans [<xref ref-type="bibr" rid="CR9_21">9</xref>, <xref ref-type="bibr" rid="CR10_21">10</xref>]. Human MPV is a recently discovered virus belonging to the Paramyxoviridae family [<xref ref-type="bibr" rid="CR11_21">11</xref>]. The human MPV genome and structure are very similar to those of RSV, and both viruses display the same surface proteins [<xref ref-type="bibr" rid="CR12_21">12</xref>]. Available data indicate that human MPV infects only humans, although this virus is believed to originate from birds [<xref ref-type="bibr" rid="CR13_21">13</xref>].<fig id="Fig2_21"><label>Fig. 21.2</label><caption><p>Diffuse alveolar consolidations in a patient co-infected with influenza and Streptococcus pneumoniae</p></caption><graphic xlink:href="150925_1_En_21_Fig2_HTML" id="MO2_21"/></fig>
</p><p>Human rhinoviruses and non-poliomyelitic enteroviruses are non-enveloped, single-stranded RNA viruses belonging to the Picornaviridae family. The <italic>Rhinovirus</italic> genus consists of more than 100 different serotypes divided into three species (A, B, and the newly described C species) based on antigenic variations in the three proteins VP1, VP2, and VP3 found on the capsid surface [<xref ref-type="bibr" rid="CR14_21">14</xref>, <xref ref-type="bibr" rid="CR15_21">15</xref>]. Enteroviruses are divided into four species (A, B, C, and D) [<xref ref-type="bibr" rid="CR16_21">16</xref>, <xref ref-type="bibr" rid="CR17_21">17</xref>]. They share the same structure as other Picornaviridae. Humans are the only natural host of these viruses [<xref ref-type="bibr" rid="CR14_21">14</xref>, <xref ref-type="bibr" rid="CR16_21">16</xref>].<fig id="Fig3_21"><label>Fig. 21.3</label><caption><p>Thoracic CT scan showing bronchiolitis pattern (bronchial wall thickening associated with ground-glass attenuation, interlobular septa thickening and tree-in-bud opacities) in an influenza-infected patient</p></caption><graphic xlink:href="150925_1_En_21_Fig3_HTML" id="MO3_21"/></fig>
</p><p>Coronaviruses are enveloped, positive-sense, single-stranded RNA viruses belonging to the Coronaviridae family [<xref ref-type="bibr" rid="CR18_21">18</xref>]. Their envelope supports two main proteins, the haemagglutinin-esterase protein and the antigenic protein S [<xref ref-type="bibr" rid="CR18_21">18</xref>]. Human coronaviruses 229E and OC43 were the predominant human respiratory coronavirus strains before the recent identification of the new human coronaviruses NL63, HKU1, and SARS [<xref ref-type="bibr" rid="CR19_21">19</xref>&#x02013;<xref ref-type="bibr" rid="CR21_21">21</xref>].</p><p>Adenoviruses are non-enveloped, double-stranded DNA viruses that form the Adenoviridae family. Six subgenera (A&#x02013;F) and 51 human serotypes of adenoviruses have been described [<xref ref-type="bibr" rid="CR22_21">22</xref>]. Adenoviruses have an icosahedral capsid made of 250 protein subunits called capsomeres [<xref ref-type="bibr" rid="CR23_21">23</xref>]. Humans are the only natural hosts of these viruses.</p></sec><sec id="Sec3_21"><title>Epidemiology</title><p>Common respiratory viruses are ubiquitous pathogens that share a number of epidemiological features. Most of them are responsible for outbreaks that occur with a remarkable seasonal pattern. These seasonal variations in viral activity occur only in temperate climates and tend to disappear in equatorial zones. This phenomenon is incompletely understood and may involve not only specific viral characteristics, but also seasonal changes in living conditions [<xref ref-type="bibr" rid="CR6_21">6</xref>]. Influenza, RSV, human MPV, and Coronavirus activities peak during the winter months [<xref ref-type="bibr" rid="CR6_21">6</xref>, <xref ref-type="bibr" rid="CR7_21">7</xref>, <xref ref-type="bibr" rid="CR18_21">18</xref>]. PIV1 and 2 cause outbreaks in the fall [<xref ref-type="bibr" rid="CR7_21">7</xref>]. Seasonality is less pronounced for PIV3 and Picornaviridae, which exhibit year-round activity with peaks in the spring for PIV3, spring and fall for human rhinoviruses, and summer and fall for non-poliomyelitic Enteroviruses [<xref ref-type="bibr" rid="CR7_21">7</xref>, <xref ref-type="bibr" rid="CR14_21">14</xref>, <xref ref-type="bibr" rid="CR16_21">16</xref>]. Little is known about the epidemiology of PIV4, since this virus is responsible for mild infections and is therefore rarely identified [<xref ref-type="bibr" rid="CR7_21">7</xref>].</p><p>Common respiratory viruses typically cause infections in early childhood. Influenza C usually causes mild infections that lead to the acquisition of protective antibodies capable of preventing recurrences [<xref ref-type="bibr" rid="CR24_21">24</xref>]. Influenza A and B are considerably more common and can cause disease of greater severity, most notably in high-risk groups, such as elderly people and patients with chronic respiratory or cardiovascular conditions, chronic renal failure, diabetes mellitus, or immune deficiencies [<xref ref-type="bibr" rid="CR6_21">6</xref>]. It is estimated that about 5% of adults and 20% of children experience an influenza episode every year throughout the world [<xref ref-type="bibr" rid="CR25_21">25</xref>]. Although most influenza episodes are mild, the high occurrence rate results in a huge burden of disease that has a severe socioeconomic impact [<xref ref-type="bibr" rid="CR6_21">6</xref>]. Influenza viruses are believed to be the seventh cause of death in the USA [<xref ref-type="bibr" rid="CR26_21">26</xref>]. Influenza A and B infections start in childhood and continue to occur throughout the life span, because antigenic variations affecting HA and, to a lesser extent NA, hamper the acquisition of protective immunity. Two mechanisms of antigenic variations have been described, antigenic drift and antigenic shift [<xref ref-type="bibr" rid="CR6_21">6</xref>]. Antigenic drift probably results from the accumulation of point mutations that occur continuously in influenza viruses, with new variants appearing annually or every few years. These new variants replace pre-existing ones by immunological selection and are only incompletely recognised by immunity resulting from exposure to earlier strains. Antigenic shift is a considerably rarer event that occurs only in influenza A and results in a virus with a completely new HA or NA [<xref ref-type="bibr" rid="CR6_21">6</xref>]. The result is an influenza pandemic due to the absence of protective immunity against the new virus. Progressive acquisition of immunity against this new strain attenuates the intensity of the epidemic over the following years. The exact genetic mechanisms of antigenic shift are incompletely known, and the emergence of pandemic strains is not predictable. Pandemic strains originate from the recombination of influenza strains circulating in different animal species, including birds, pigs, and humans [<xref ref-type="bibr" rid="CR6_21">6</xref>]. Five pandemics occurred in the twentieth century, and the 2009 &#x0201c;Mexican flu&#x0201d; pandemic due to the new H1N1 influenza virus is the first pandemic in the twenty-first century [<xref ref-type="bibr" rid="CR6_21">6</xref>, <xref ref-type="bibr" rid="CR27_21">27</xref>]. RSV and PIV are typically infections of early childhood [<xref ref-type="bibr" rid="CR7_21">7</xref>]. RSV and, to a lesser extent, PIV also undergo antigenic changes that lead to recurrences throughout the life span. These recurrences may be severe, especially in patients with chronic respiratory conditions and in the elderly. The burden of RSV-related diseases may be comparable to that of influenza [<xref ref-type="bibr" rid="CR28_21">28</xref>].</p><p>Few data are available on the specific epidemiological characteristics of common respiratory viruses in patients with HMs. Reported incidence rates vary widely, from 1.8% to 30% [<xref ref-type="bibr" rid="CR29_21">29</xref>, <xref ref-type="bibr" rid="CR30_21">30</xref>]. This variability may be explained by disparities in the type of patients enrolled, reasons for screening patients for respiratory viruses and, most importantly, diagnostic methods used. Whatever the exact incidence, one can reasonably assume that attack rates of common respiratory viruses in immunocompromised patients are closely related to the prevalence of respiratory viruses in the community, which serves as the viral reservoir for immunocompromised patients [<xref ref-type="bibr" rid="CR31_21">31</xref>]. This has been confirmed in recent studies showing that the occurrence of viral respiratory diseases in the enrolled immunocompromised patients paralleled the concomitant viral activity in the community [<xref ref-type="bibr" rid="CR32_21">32</xref>, <xref ref-type="bibr" rid="CR33_21">33</xref>]. Accordingly, influenza viruses and RSV are the viruses most commonly identified in the largest cohorts of HM patients, each accounting for about one-third of viral respiratory events [<xref ref-type="bibr" rid="CR34_21">34</xref>&#x02013;<xref ref-type="bibr" rid="CR36_21">36</xref>]. PIV, Picornaviridae, and adenoviruses come next. It must be pointed out that influenza viruses accounted for a much higher proportion (up to 75%) of viral respiratory events in the study by Martino et al. conducted in the setting of a major influenza outbreak in the community [<xref ref-type="bibr" rid="CR32_21">32</xref>].</p><p>Adenovirus epidemiology in patients with HM deserves special attention. Similar to other common respiratory viruses, adenoviruses cause primary infections in childhood, usually during the first few years of life. Adenoviruses may account for 5% to 10% of viral respiratory infections in children [<xref ref-type="bibr" rid="CR23_21">23</xref>], and also cause outbreaks in closed and semi-closed populations of young adults such as the military [<xref ref-type="bibr" rid="CR37_21">37</xref>, <xref ref-type="bibr" rid="CR38_21">38</xref>]. A distinctive feature of adenoviruses is the ability to cause chronic latent infection by persisting in lymphoepithelial tissues, most notably in the nasopharynx [<xref ref-type="bibr" rid="CR23_21">23</xref>]. The epidemiology of adenoviruses in patients with HM has not been the focus of specific studies. Nevertheless, exogenous contamination, by the respiratory or oro-faecal route, may be less important than reactivation of the latent virus [<xref ref-type="bibr" rid="CR39_21">39</xref>]. Thus, adenoviral infections in patients with HM may be related chiefly to the level of immunosuppression and, perhaps, to unknown viral factors driving reactivation, rather than to the level of viral activity in the community.</p><p>The epidemiologic characteristics of influenza, RSV, and PIV are particularly well known, perhaps in part because infections with these viruses are considerably more common compared to those due to other viruses. However, the availability of simple and rapid diagnostic tools for these three viruses probably played a great role. Since Picornaviridae, Coronaviridae, and the newly discovered human MPV are mainly diagnosed using reverse-transcriptase polymerase-chain-reaction technology (rt-PCR), data on their epidemiology are still limited. Recent studies using rt-PCR detection of respiratory viruses in patients with HM revealed a high incidence of human MPV infections, similar to that of RSV infections [<xref ref-type="bibr" rid="CR30_21">30</xref>, <xref ref-type="bibr" rid="CR36_21">36</xref>]. In the near future, studies using molecular biology tools may help to clarify the epidemiology of common respiratory viruses and may lead to a radical change in current concepts.</p></sec><sec id="Sec4_21"><title>Clinical Manifestations</title><p>Common respiratory virus infections have been studied chiefly in patients receiving high-dose chemotherapy and haematopoietic stem cell transplantation (HSCT). Compared with immunocompetent patients, several distinctive features have been reported. Viral shedding lasts longer and progression to pneumonia is more common [<xref ref-type="bibr" rid="CR31_21">31</xref>]. Late airflow obstruction has been reported in HSCT recipients [<xref ref-type="bibr" rid="CR40_21">40</xref>]. Some respiratory viruses are responsible for extra-respiratory manifestations. Although rare in immunocompetent hosts, these manifestations might be more common in patients with HM.</p><p>Common respiratory viral infections in patients with HM are characterized by prolonged viral shedding. A median duration of 2 weeks was found in most studies [<xref ref-type="bibr" rid="CR30_21">30</xref>, <xref ref-type="bibr" rid="CR32_21">32</xref>, <xref ref-type="bibr" rid="CR33_21">33</xref>, <xref ref-type="bibr" rid="CR36_21">36</xref>]. However, viral shedding may last for months in some cases [<xref ref-type="bibr" rid="CR41_21">41</xref>, <xref ref-type="bibr" rid="CR42_21">42</xref>]. In addition, the amount of virus shed per day may be greater in HM patients than in immunocompetent individuals [<xref ref-type="bibr" rid="CR43_21">43</xref>]. Similarly to findings in immunocompromised patients, children shed more viruses over a longer period than do adults [<xref ref-type="bibr" rid="CR31_21">31</xref>]. This prolonged high-load viral shedding is of critical importance, since it may enhance both viral dissemination [<xref ref-type="bibr" rid="CR43_21">43</xref>, <xref ref-type="bibr" rid="CR44_21">44</xref>] and the emergence of resistant strains via prolonged exposure to antiviral drugs [<xref ref-type="bibr" rid="CR41_21">41</xref>, <xref ref-type="bibr" rid="CR42_21">42</xref>].</p><p>As stated above, common respiratory viruses have long been underrecognised in patients with HM. In the 1990s, the first reports of common respiratory virus infections focused on influenza and RSV [<xref ref-type="bibr" rid="CR45_21">45</xref>&#x02013;<xref ref-type="bibr" rid="CR50_21">50</xref>]. In these studies, progression to pneumonia occurred in about 75% of patients infected with influenza viruses and 50% of those infected with RSV, and was associated with mortality rates of 25% for influenza and about 80% for RSV. One possible explanation for these striking observations may be a surge of interest in respiratory viral infections in HM patients that led to the publication of the most severe cases. Not surprisingly, these studies had small numbers of patients and high rates of nosocomial infections.</p><p>More recently, studies of large patient cohorts led to better characterization of influenza-related pneumonia in patients with HM [<xref ref-type="bibr" rid="CR29_21">29</xref>, <xref ref-type="bibr" rid="CR32_21">32</xref>&#x02013;<xref ref-type="bibr" rid="CR34_21">34</xref>]. About one-third of patients develop lower respiratory tract infection (LRTI). Although less common than in previous reports, influenza-related pneumonia remains a severe condition with a 15&#x02013;30% mortality rate. As in immunocompetent hosts, upper respiratory tract infection (URTI) is almost always present and often precedes LRTI [<xref ref-type="bibr" rid="CR32_21">32</xref>, <xref ref-type="bibr" rid="CR49_21">49</xref>, <xref ref-type="bibr" rid="CR51_21">51</xref>, <xref ref-type="bibr" rid="CR52_21">52</xref>]. URTI can be considered a useful argument supporting the diagnosis of respiratory viral infection in patients with HM investigated for pneumonia [<xref ref-type="bibr" rid="CR53_21">53</xref>]. However, the identification of a common respiratory virus does not exclude an associated bacterial or fungal infection. These co-infections are very frequent, occurring in 12&#x02013;25% of cases of influenza-related pneumonia [<xref ref-type="bibr" rid="CR32_21">32</xref>, <xref ref-type="bibr" rid="CR34_21">34</xref>, <xref ref-type="bibr" rid="CR50_21">50</xref>]. There are no reports of extra-respiratory manifestations in patients with HM, although myocarditis, pericarditis, myositis, meningo-encephalitis, Guillain-Barr&#x000e9; syndrome, and Reye syndrome have been described in immunocompetent patients [<xref ref-type="bibr" rid="CR6_21">6</xref>, <xref ref-type="bibr" rid="CR54_21">54</xref>].</p><p>RSV-related pneumonia is now believed to complicate about 30&#x02013;40% of RSV infections in patients with HM [<xref ref-type="bibr" rid="CR32_21">32</xref>, <xref ref-type="bibr" rid="CR34_21">34</xref>, <xref ref-type="bibr" rid="CR47_21">47</xref>]. Again, mortality remains high, ranging from 15% to 30%. URTI is a common clinical manifestation. No clear data on the incidence of concomitant bacterial or fungal infections are available in the literature, and RSV-related pneumonia in patients with HM are often ascribed to viral infection [<xref ref-type="bibr" rid="CR53_21">53</xref>]. However, bacterial co-infections were present in as many as 30% of patients in a large study of RSV infections in immunocompetent individuals [<xref ref-type="bibr" rid="CR55_21">55</xref>]. Bacterial or fungal co-infection may be more common in patients with HM and must be carefully sought. Non-sustained viraemia may accompany RSV infection, and RSV was associated with cardiac arrhythmias and neurological disorders in two case reports [<xref ref-type="bibr" rid="CR8_21">8</xref>, <xref ref-type="bibr" rid="CR56_21">56</xref>]. However, no extra-respiratory manifestations of RSV infection have been described in immunocompromised patients.</p><p>PIV infections have also been studied in patients with HM [<xref ref-type="bibr" rid="CR34_21">34</xref>, <xref ref-type="bibr" rid="CR57_21">57</xref>]. PIV type 3 was the cause in 90% of reported cases. In these studies, PIV-related pneumonia was comparable to influenza-related pneumonia, with about one third of patients being affected, a high rate of concomitant URTI, and a 15&#x02013;30% mortality rate. Co-infections were found in as many as 53% of the patients studied by Nichols et al. [<xref ref-type="bibr" rid="CR57_21">57</xref>]. However, in a recent study using rt-PCR for routine respiratory virus detection in HSCT recipients, PIV was found in respiratory samples of asymptomatic patients [<xref ref-type="bibr" rid="CR30_21">30</xref>], whereas influenza, RSV, and human MPV were not detected. This finding suggests that studies using conventional diagnostic methods may have overestimated the true severity of PIV in patients with HM. Some reports suggested a role for PIV3 in the occurrence of neurologic manifestations (such as meningitis, encephalitis, and Guillain-Barr&#x000e9; syndrome) and myocarditis [<xref ref-type="bibr" rid="CR58_21">58</xref>]. Such manifestations have not been reported in immunocompromised patients.</p><p>Case reports suggest that the recently discovered human MPV may induce severe pneumonia in patients with HM [<xref ref-type="bibr" rid="CR59_21">59</xref>&#x02013;<xref ref-type="bibr" rid="CR61_21">61</xref>]. To our knowledge, two retrospective cohorts [<xref ref-type="bibr" rid="CR62_21">62</xref>, <xref ref-type="bibr" rid="CR63_21">63</xref>] and three prospective cohorts [<xref ref-type="bibr" rid="CR30_21">30</xref>, <xref ref-type="bibr" rid="CR36_21">36</xref>, <xref ref-type="bibr" rid="CR64_21">64</xref>] describing human MPV infections in patients with HM have been published. The small number of patients and highly variable results (pneumonia in 0&#x02013;43% of patients with a 0&#x02013;40% mortality rate) preclude definitive conclusions about human MPV-related pneumonia in patients with HM. Although debated, the occurrence of asymptomatic viral shedding may suggest lesser severity of human MPV-related pneumonia compared to influenza and RSV [<xref ref-type="bibr" rid="CR30_21">30</xref>, <xref ref-type="bibr" rid="CR65_21">65</xref>]. Two cases of encephalitis with human MPV detected in cerebrospinal fluid in immunocompetent paediatric patients have been published [<xref ref-type="bibr" rid="CR66_21">66</xref>, <xref ref-type="bibr" rid="CR67_21">67</xref>]. No extra-respiratory manifestations have been reported in patients with HM.</p><p>Since the identification of Picornaviridae and Coronaviridae relies chiefly on molecular biology tools, only limited data are available about their contribution to respiratory viral infections in patients with HM. Epidemiological evidence supports an association of human rhinovirus with LRTI in immunocompetent children and elderly people [<xref ref-type="bibr" rid="CR68_21">68</xref>, <xref ref-type="bibr" rid="CR69_21">69</xref>]. Despite growing evidence that human rhinovirus is able to replicate in lower respiratory tract cells in vitro and in vivo [<xref ref-type="bibr" rid="CR70_21">70</xref>, <xref ref-type="bibr" rid="CR71_21">71</xref>], whether this virus can cause pneumonia remains debated [<xref ref-type="bibr" rid="CR72_21">72</xref>]. Several reports in patients with HM link human rhinovirus to LRTI [<xref ref-type="bibr" rid="CR73_21">73</xref>&#x02013;<xref ref-type="bibr" rid="CR77_21">77</xref>]. However, these retrospective studies in small patient populations with high rates of pulmonary co-pathogen identification fail to demonstrate a clear role for human rhinovirus in the development of pneumonia. Non-poliomyelitic enteroviruses are chiefly responsible for URTI [<xref ref-type="bibr" rid="CR16_21">16</xref>]. Only a few studies with small numbers of patients have focused on these viruses in patients with HM, and no conclusions can be drawn from their results [<xref ref-type="bibr" rid="CR77_21">77</xref>&#x02013;<xref ref-type="bibr" rid="CR80_21">80</xref>]. Coronaviridae are also principally responsible for URTI but may occasionally cause pneumonia [<xref ref-type="bibr" rid="CR81_21">81</xref>]. No studies have evaluated the role of Coronaviridae in patients with HM, and only two case reports have been published [<xref ref-type="bibr" rid="CR82_21">82</xref>, <xref ref-type="bibr" rid="CR83_21">83</xref>].</p><p>Although it is now clear that most of the common respiratory viruses are responsible for an increased rate of pneumonia in patients with HM (Table <xref rid="Tab1_21" ref-type="table">21.1</xref> and Fig. <xref rid="Tab1_21" ref-type="table">21.1</xref>&#x02013;<xref rid="Tab3_21" ref-type="table">21.3</xref>), the exact nature and causative mechanisms of pneumonia in this situation remain unknown. The only risk factor for virus-related pneumonia found consistently in studies is lymphocytopenia, defined using a variety of cutoffs [<xref ref-type="bibr" rid="CR29_21">29</xref>, <xref ref-type="bibr" rid="CR32_21">32</xref>&#x02013;<xref ref-type="bibr" rid="CR34_21">34</xref>]. One study found that lymphocytopenia (absolute lymphocyte count less than 200 cells/mL) was independently associated with mortality in patients with influenza-related pneumonia [<xref ref-type="bibr" rid="CR34_21">34</xref>]. A higher incidence and greater severity of virus-related pneumonia have been noted in HSCT recipients compared with other patients with HM. This finding may reflect deeper lymphocyte depletion. However, in a study by Martino et al., pneumonia rates were comparable in patients with and without lymphocytopenia [<xref ref-type="bibr" rid="CR32_21">32</xref>]. The possible higher incidence and greater severity of virus-related pneumonia within the first few days after HSCT, compared with infections occurring later on, may reflect deeper lymphocyte depletion [<xref ref-type="bibr" rid="CR53_21">53</xref>]. A similar mechanism may underlie the surprising protective effect of corticosteroid therapy in the study by Nichols et al., since this treatment is often given to treat graft-versus-host disease (GVHD) after lymphoid engraftment [<xref ref-type="bibr" rid="CR33_21">33</xref>].<table-wrap id="Tab1_21"><label>Table 21.1</label><caption><p>Clinical manifestations of influenza, respiratory syncytial virus (RSV), parainfluenza virus (PIV), human metapneumovirus (hMPV), and adenovirus in patients with haematological malignancies</p></caption><table frame="hsides" rules="groups"><thead><tr><th/><th>Influenza</th><th>RSV</th><th>PIV</th><th>hMPV</th><th>Adenovirus</th></tr></thead><tbody><tr><td>Pneumonia rate (%)</td><td>33</td><td>30&#x02013;40</td><td>Up to 30<sup>a</sup>
</td><td>Up to 40<sup>a</sup>
</td><td>NA</td></tr><tr><td>Coinfection rate (%)</td><td>12&#x02013;25</td><td>NA</td><td>Up to 50<sup>a</sup>
</td><td>NA</td><td>50</td></tr><tr><td>Mortality rate (%)</td><td>15&#x02013;30</td><td>15&#x02013;30</td><td>15&#x02013;30<sup>a</sup>
</td><td>Up to 40<sup>a</sup>
</td><td>50&#x02013;80</td></tr><tr><td>Asymptomatic shedding</td><td>No</td><td>No</td><td>Yes</td><td>Yes</td><td>No</td></tr></tbody></table><table-wrap-foot><p>
<italic>NA</italic> not available</p><p>
<sup>a</sup>The occurrence of asymptomatic viral shedding may indicate lesser severity than previously thought</p></table-wrap-foot></table-wrap>
</p><p>Common respiratory viruses increase mortality in patients with HM mainly by causing severe pneumonia, but they may also contribute to a long-term decline in pulmonary function. RSV, PIV, and influenza infections have been linked to late airflow obstruction in HSCT recipients [<xref ref-type="bibr" rid="CR40_21">40</xref>]. In a study focusing specifically on the role of respiratory viruses in late airflow obstruction, PIV LRTI was the strongest risk factor, followed by PIV URTI [<xref ref-type="bibr" rid="CR84_21">84</xref>]. Pneumonia caused by RSV was a borderline-significant risk factor. The exact causative mechanisms remain unknown, but inflammation resulting from prolonged viral persistence and pneumonia-induced post-acute-phase inflammation have been suggested as possible factors [<xref ref-type="bibr" rid="CR84_21">84</xref>, <xref ref-type="bibr" rid="CR85_21">85</xref>].</p><p>A distinctive feature of adenoviruses in HM patients is that they may either be acquired via exogenous respiratory or oro-faecal contamination, or arise via reactivation of latent viruses [<xref ref-type="bibr" rid="CR39_21">39</xref>, <xref ref-type="bibr" rid="CR86_21">86</xref>]. Adenoviruses cause a wide spectrum of clinical manifestations ranging from benign conjunctivitis to rapidly fatal disseminated disease. In patients with HM, the risk of severe adenoviral disease seems related to the level of immunosuppression. Adenoviral disease has been reported in 3&#x02013;27% of HSCT recipients within the first 100 days after transplantation [<xref ref-type="bibr" rid="CR87_21">87</xref>&#x02013;<xref ref-type="bibr" rid="CR89_21">89</xref>]. Higher rates may occur in paediatric patients compared with adults [<xref ref-type="bibr" rid="CR88_21">88</xref>, <xref ref-type="bibr" rid="CR90_21">90</xref>]. In vivo and ex vivo graft T-cell depletion [<xref ref-type="bibr" rid="CR86_21">86</xref>, <xref ref-type="bibr" rid="CR87_21">87</xref>, <xref ref-type="bibr" rid="CR91_21">91</xref>], lymphocytopenia [<xref ref-type="bibr" rid="CR86_21">86</xref>], GVHD [<xref ref-type="bibr" rid="CR87_21">87</xref>, <xref ref-type="bibr" rid="CR89_21">89</xref>], viral shedding from more than one site [<xref ref-type="bibr" rid="CR86_21">86</xref>, <xref ref-type="bibr" rid="CR88_21">88</xref>, <xref ref-type="bibr" rid="CR90_21">90</xref>], and adenovirus viraemia [<xref ref-type="bibr" rid="CR86_21">86</xref>, <xref ref-type="bibr" rid="CR92_21">92</xref>&#x02013;<xref ref-type="bibr" rid="CR94_21">94</xref>] have been reported as risk factors for severe adenoviral disease. Adenovirus viraemia consistently preceded viral shedding from more than one site in the study by Chakrabarti et al. [<xref ref-type="bibr" rid="CR86_21">86</xref>]. This risk factor is of critical importance since it guides pre-emptive antiviral therapy. Adenoviral disease has been chiefly reported in myeloablative HSCT recipients, but has also been described in non-myeloablative HSCT recipients, autologous transplant recipients, and patients with chronic lymphocytic leukaemia treated with fludarabine combined with CD52 monoclonal antibodies [<xref ref-type="bibr" rid="CR88_21">88</xref>, <xref ref-type="bibr" rid="CR89_21">89</xref>]. In allogeneic transplant recipients, the most frequent manifestations of adenoviral infection are gastrointestinal disease and haemorrhagic cystitis [<xref ref-type="bibr" rid="CR95_21">95</xref>, <xref ref-type="bibr" rid="CR96_21">96</xref>]. Although haemorrhagic cystitis is a benign localised event, it is associated with high morbidity [<xref ref-type="bibr" rid="CR90_21">90</xref>]. It must be pointed out that in a patient with febrile haematuria and adenovirus urinary excretion, the onset of acute renal failure with flank pain may reveal adenovirus nephritis [<xref ref-type="bibr" rid="CR97_21">97</xref>]. Gastrointestinal manifestations include gastroenteritis and colitis, which often manifest as febrile haemorrhagic diarrhoea [<xref ref-type="bibr" rid="CR95_21">95</xref>, <xref ref-type="bibr" rid="CR98_21">98</xref>]. The most severe manifestations of adenoviral infection are hepatitis, encephalitis, and pneumonia [<xref ref-type="bibr" rid="CR86_21">86</xref>, <xref ref-type="bibr" rid="CR89_21">89</xref>, <xref ref-type="bibr" rid="CR90_21">90</xref>]. Adenovirus-related pneumonia occurred in 15 of the 85 patients with adenovirus infection in the study by La Rosa et al. [<xref ref-type="bibr" rid="CR89_21">89</xref>]. The pneumonia was isolated in 11 patients and a manifestation of disseminated disease in 4 patients. Bacterial and fungal co-infections were found in 50% of patients, in keeping with other studies [<xref ref-type="bibr" rid="CR90_21">90</xref>]. The mortality rate was 73% overall, 50% in patients with isolated pneumonia, and 80% in patients with disseminated disease [<xref ref-type="bibr" rid="CR89_21">89</xref>].</p></sec><sec id="Sec5_21"><title>Diagnosis</title><p>Respiratory viral infections are the second most common cause of community-acquired pneumonia [<xref ref-type="bibr" rid="CR2_21">2</xref>, <xref ref-type="bibr" rid="CR99_21">99</xref>]. They were long considered a simple differential diagnosis, without practical consequences for the patient. Recently, however, the diagnosis of viral respiratory infection has become increasingly relevant for medical care [<xref ref-type="bibr" rid="CR100_21">100</xref>, <xref ref-type="bibr" rid="CR101_21">101</xref>]. First, RSV, influenza, PIV, and adenoviruses have been identified as significant causes of community-acquired and nosocomial respiratory infections [<xref ref-type="bibr" rid="CR29_21">29</xref>, <xref ref-type="bibr" rid="CR102_21">102</xref>]. Second, new nucleic acid-based assays have been shown to be more sensitive than conventional techniques. Third, specific antiviral drugs are now available for some respiratory viruses, including influenza and adenovirus. Several diagnostic tests have been introduced for the detection of respiratory viruses. The main characteristics of the most widely used assays are shown in Table <xref rid="Tab2_21" ref-type="table">21.2</xref>.<table-wrap id="Tab2_21"><label>Table 21.2</label><caption><p>Methods for detecting common respiratory viruses</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Test</th><th>Sensitivity</th><th>Specificity</th><th>Time to result</th><th>Viral targets</th><th>Cost</th></tr></thead><tbody><tr><td>Immunofluorescence staining</td><td>++</td><td>++</td><td>&#x0003c;3 h</td><td>&#x0003c;8</td><td>15&#x02013;25 Euros</td></tr><tr><td>Rapid antigen testing (immunochromatography)</td><td>+</td><td>+/++</td><td>&#x0003c;1 h</td><td>Only available for influenza and RSV</td><td>10&#x02013;15 Euros per test</td></tr><tr><td>Cell culture</td><td>+</td><td>+++</td><td>Days to weeks</td><td>Depending on the cell lines used</td><td>NA</td></tr><tr><td>Monoplex NASBA or real-time PCR assay</td><td>+++</td><td>+++</td><td>&#x0003c;12 h</td><td>1 or 2 per reaction</td><td>10&#x02013;20 Euros per target</td></tr><tr><td>Multiplex molecular assay</td><td>+++</td><td>++/+++</td><td>6 h&#x02013;24 h</td><td>12&#x02013;20 per reaction in 1 or 2 tubes</td><td>50&#x02013;80 Euros per panel</td></tr></tbody></table></table-wrap>
</p><p>High-quality clinical specimens are needed to ensure the accurate detection of respiratory viruses. Indeed, respiratory virus detection requires a large number of epithelial cells, since viruses are intracellular pathogens. Nasopharyngeal aspirates and nasopharyngeal washes are recognised to be superior to other sample types for detecting respiratory viruses [<xref ref-type="bibr" rid="CR103_21">103</xref>, <xref ref-type="bibr" rid="CR104_21">104</xref>]. Because the collection process is unpleasant and time-consuming, causes patient discomfort, and requires a suction device, flocked swabs were recently introduced for respiratory sample collection. Flocked swabs were found to improve the collection and release of epithelial cells [<xref ref-type="bibr" rid="CR105_21">105</xref>, <xref ref-type="bibr" rid="CR106_21">106</xref>], and were recently recommended for the diagnosis of the new pandemic H1N1 influenza strain. The number of cells collected is lower with flocked swabs than with nasopharyngeal aspirates, but seems sufficient for respiratory virus detection by immunofluorescence [<xref ref-type="bibr" rid="CR105_21">105</xref>, <xref ref-type="bibr" rid="CR106_21">106</xref>]. Flocked swab collection is sensitive, specific, easy to use, and better tolerated by patients, and may therefore constitute a good alternative to nasopharyngeal aspiration. Because most respiratory viruses have high replication rates in the upper respiratory tract, nasopharyngeal secretions are usually sufficient to diagnose respiratory viral infections. However, asymptomatic respiratory virus shedding in the upper respiratory tract may occur even in immunocompromised patients, and URTI may be followed by LRTI, particularly during influenza infections. Thus, virus detection in lungs via bronchoalveolar lavage may be useful to assess the causative role for the virus.</p><p>Over the past 2 decades, virus isolation and antigen detection have been the mainstay of clinical laboratory testing for respiratory virus infections. Virus isolation required several cell lines and was mainly performed on shell vial cultures. The diagnosis was based on the presence of the cytopathic effect, which requires several days or weeks to develop. To shorten the time to diagnosis, specific monoclonal antibodies were introduced to enable the detection of specific viral antigens within 1&#x02013;2 days. Direct or indirect fluorescent antibody staining of cells from respiratory specimens (mainly nasopharyngeal swabs or nasopharyngeal aspirates [NPA] and bronchoalveolar lavage fluid) is commonly used to detect viral antigens. In many laboratories, the first-line test is immunofluorescence staining, which requires very little material and provides a result within about 3 h. However commercial monoclonal antibodies are available for a limited number of targets, including influenza A and B; RSV; adenovirus; PIV 1, 2 and 3; and human MPV. Thus, rhinoviruses and coronaviruses, the most frequent causes of URTI and the most recently discovered agents, cannot be detected using monoclonal antibodies.</p><p>Nucleic acid amplification tests have been proven to be rapid, very sensitive, and specific. The early tests, including PCR, nucleic acid sequence-based amplification (NASBA), and real-time PCR assays, were developed in monoplex format. Despite the gain in sensitivity and the ability to test for most respiratory viruses, the need to carry out as many PCR tests as targets has limited the use of this method. None of the current PCR assays has sufficiently high throughput to handle large numbers of samples containing multiple targets. Over the last few years, assays have been introduced in multiplex format. Different technologies have been used. In addition, sensitivities may be lower compared to monoplex real-time RT-PCR. Multiplex PCR procedures are difficult to optimise, because each amplification target corresponds to a set of primers characterized by a unique combination of optimal annealing conditions. Multiple primers included in a single tube may also result in primer-primer interference and in nonspecific nucleic acid amplification.</p><p>Currently, several multiplex assays can detect up to nine respiratory viruses in a single reaction. Real-time multiplex assays detect up to five targets in a single reaction, depending on the number of channels available in the real-time PCR machine [<xref ref-type="bibr" rid="CR107_21">107</xref>&#x02013;<xref ref-type="bibr" rid="CR110_21">110</xref>]. Existing multiplex PCR assays that use agarose gel electrophoresis or capillary electrophoresis as the detection system or multiplex PCR assays combined with an enzyme-linked immunosorbent assay can detect five to nine targets per reaction [<xref ref-type="bibr" rid="CR111_21">111</xref>&#x02013;<xref ref-type="bibr" rid="CR113_21">113</xref>].</p><p>More recently introduced techniques can detect up to 20 targets in one or two tubes. These include the four techniques detailed below.
<list list-type="order"><list-item><p>
<italic>Low-density micro-array</italic> based on cDNA spots that are immobilised on a polymer-coated slide and that hybridise with specific DNA sequences previously amplified from the sample using PCR. Hybridisation is detected based on the production of an insoluble product on the microarray at the sites where amplified DNA products are captured by the probes [<xref ref-type="bibr" rid="CR114_21">114</xref>].</p></list-item><list-item><p>
<italic>Multiplex detection based on Luminex</italic> technology. The PCR products are coupled with spectrally distinct fluorescence-labelled micro-beads, which are detected by flow cytometry [<xref ref-type="bibr" rid="CR115_21">115</xref>, <xref ref-type="bibr" rid="CR116_21">116</xref>].</p></list-item><list-item><p>
<italic>Multiplex ligation-dependent probe amplification (MLPA)</italic> involves specific viral amplification followed by amplification after hybridisation and binding of virus-specific probes to the PCR product. Identification is accomplished by PCR fragment size analysis using gel electrophoresis methods [<xref ref-type="bibr" rid="CR117_21">117</xref>, <xref ref-type="bibr" rid="CR118_21">118</xref>].</p></list-item><list-item><p>
<italic>Mass spectrometry</italic> assays for respiratory virus detection are based on the analysis of base compositions in RT-PCR amplicons [<xref ref-type="bibr" rid="CR119_21">119</xref>].</p></list-item></list>
</p><p>Most assays exhibited specificities comparable to those of cell culture and monoplex real-time reverse transcription (RT)-PCR, and sensitivities similar to those of monoplex (RT)-PCR assays.</p><p>Although molecular assays, particularly RT-PCR, provide same-day results, they require a nucleic acid extraction step. This step increases the time to results compared to antigen detection by fluorescent staining. Molecular assays should be performed as often as possible to improve patient care by shortening the hospital stay, curtailing or preventing antibiotic therapy, preventing nosocomial spread, and allowing specific antiviral therapy. Therefore, and given the cost of the equipment needed (RT-PCR machine, sequencer, luminex, nucleic acid extractor, DNA chip reader, mass spectrometer), molecular assays will probably be chiefly performed in laboratories receiving large numbers of samples per day.</p><p>Few data are available on the exhaustive and sensitive detection of respiratory viruses in HM patients. Recent data show that using molecular assays increases the virus detection rate twofold compared to cultures and fourfold compared to immunofluorescence staining [<xref ref-type="bibr" rid="CR120_21">120</xref>]. Two prospective studies of molecular assays in HSCT recipients documented persistent asymptomatic respiratory shedding of PIV and human MPV [<xref ref-type="bibr" rid="CR30_21">30</xref>, <xref ref-type="bibr" rid="CR65_21">65</xref>]. These data emphasise the need for prospective studies of the molecular detection of respiratory viruses to elucidate factors associated with symptomatic or asymptomatic respiratory viral infection and to help in the interpretation of positive assays in HM patients.</p><sec id="Sec6_21"><title>Antiviral Treatment</title><p>A chapter from Dr. Sandherr is dedicated to antiviral therapy in this book. Regarding common viruses, we will briefly describe available treatments on influenza and RSV. Two classes of antiviral drugs are available for the treatment of influenza: M2 ion channel inhibitors and neuraminidase inhibitors. The M2 ion channel inhibitors, amantadine and rimantadine, act by inhibiting the M2 protein needed for viral RNA release within the host cells. They are active only against influenza A strains. Their clinical effect is limited, being not significantly different from that of a placebo [<xref ref-type="bibr" rid="CR121_21">121</xref>], and is further hampered by the worldwide emergence of resistant influenza A strains [<xref ref-type="bibr" rid="CR122_21">122</xref>]. The neuraminidase inhibitors (Table <xref rid="Tab3_21" ref-type="table">21.3</xref>), oral oseltamivir and inhaled zanamivir, are sialic acid analogues that competitively inhibit the influenza neuraminidase. Randomised controlled trials showed moderate decreases in symptom intensity and duration with both drugs [<xref ref-type="bibr" rid="CR123_21">123</xref>&#x02013;<xref ref-type="bibr" rid="CR125_21">125</xref>]. Neuraminidase inhibitors may also limit bacterial super-infection of the lungs [<xref ref-type="bibr" rid="CR125_21">125</xref>, <xref ref-type="bibr" rid="CR126_21">126</xref>]. Early administration of these drugs seems mandatory to obtain a clinical benefit [<xref ref-type="bibr" rid="CR127_21">127</xref>]. A more recent cohort study suggested a diminution of 15-day mortality with neuraminidase inhibitors [<xref ref-type="bibr" rid="CR128_21">128</xref>]. This result must be interpreted with caution, especially given the study design. There is growing concern about the emergence of oseltamivir-resistant influenza A strains [<xref ref-type="bibr" rid="CR129_21">129</xref>]. This phenomenon is not surprising given the high mutation rate in the influenza genome. It should lead clinicians to reconsider the indications of neuraminidase inhibitors and their use as monotherapy to treat influenza [<xref ref-type="bibr" rid="CR130_21">130</xref>]. No randomised controlled trials have evaluated the efficacy of neuraminidase inhibitors in patients with HM. The apparently lower mortality in descriptive cohort studies compared with historical studies must be interpreted with caution [<xref ref-type="bibr" rid="CR33_21">33</xref>&#x02013;<xref ref-type="bibr" rid="CR35_21">35</xref>, <xref ref-type="bibr" rid="CR131_21">131</xref>]. Many of the patients in these cohorts had bacterial and fungal co-infections, whose specific treatment probably contributed to decreasing mortality. Furthermore, the decision to treat patients was left to clinician discretion, which may have introduced a bias toward selection of patients with greater disease severity. Given both the absence of strong evidence supporting beneficial effects of neuraminidase inhibitor therapy and the rapid emergence of resistant strains, we believe that neuraminidase inhibitor therapy cannot be recommended for HM patients with influenza. Randomised controlled trials are needed to determine the efficacy, safety, and ecological impact of neuraminidase inhibitors in these patients.<table-wrap id="Tab3_21"><label>Table 21.3</label><caption><p>Antiviral treatments for common viral pneumonia</p></caption><table frame="hsides" rules="groups"><thead><tr><th/><th>Oseltamivir</th><th>Zanamivir</th><th>Ribavirin</th><th>Cidofovir</th></tr></thead><tbody><tr><td>Therapeutic class</td><td>Neuraminidase inhibitor</td><td>Neuraminidase inhibitor</td><td>Nucleoside analogue</td><td>Nucleoside analogue</td></tr><tr><td>Route</td><td>Oral</td><td>Inhaled</td><td>Inhaled</td><td>Intravenous</td></tr><tr><td>Regimen</td><td>75 mg <italic>bid</italic>
</td><td>10 mg <italic>bid</italic>
</td><td>Up to 2 g <italic>tid</italic>
<sup>a</sup>
</td><td>5 mg/kg weekly<sup>a</sup>
</td></tr><tr><td>Duration</td><td>5 days</td><td>5 days</td><td>10 days<sup>a</sup>
</td><td>Variable<sup>b</sup>
</td></tr><tr><td>Side effects</td><td>Rash</td><td>Rash bronchospasm</td><td>Haemolytic anaemia<sup>d</sup> bronchospasm</td><td>Nephrotoxicity<sup><bold>c</bold></sup> myelosuppression retinitis</td></tr><tr><td>Indication</td><td>Influenza</td><td>Influenza</td><td>RSV<sup>e</sup>
</td><td>Adenovirus<sup>e</sup>
</td></tr><tr><td>Evidence supporting use</td><td>Cohort studies</td><td>Cohort studies</td><td>Cohort studies</td><td>Cohort studies</td></tr></tbody></table><table-wrap-foot><p>
<italic>NA</italic> not available, <italic>bid</italic> twice daily, <italic>tid</italic> three times daily</p><p>
<sup>a</sup>The therapeutic regimens are those described in the available literature</p><p>
<sup>b</sup>Cidofovir is given in a dose of 5 mg/kg weekly for 2 weeks then every 2 weeks according to the clinical response</p><p>
<sup><bold>c</bold></sup>Hyperhydratation and probenecide may help to prevent cidofovir nephrotoxicity</p><p>
<sup>d</sup>Haemolytic anaemia may be readily controlled by blood transfusion</p><p>
<sup>e</sup>These drugs have not been approved by regulating authorities in these indications</p></table-wrap-foot></table-wrap>
</p><p>Ribavirin is the only available antiviral drug for Paramyxoviridae infection (Table <xref rid="Tab3_21" ref-type="table">21.3</xref>). The efficacy of aerosolized ribavirin was variable in uncontrolled cohorts of patients with RSV-related pneumonia [<xref ref-type="bibr" rid="CR34_21">34</xref>, <xref ref-type="bibr" rid="CR46_21">46</xref>, <xref ref-type="bibr" rid="CR132_21">132</xref>]. Again, the results must be interpreted with caution. Early ribavirin therapy, introduced before the onset of respiratory failure, seemed associated with lower mortality in the study by Whimbey et al. [<xref ref-type="bibr" rid="CR132_21">132</xref>]. This observation led some authors to evaluate pre-emptive ribavirin therapy, characterised by ribavirin treatment of RSV URTI to prevent progression to pneumonia [<xref ref-type="bibr" rid="CR133_21">133</xref>, <xref ref-type="bibr" rid="CR134_21">134</xref>]. The study by Boeckh et al. is the only randomised controlled trial evaluating pre-emptive ribavirin therapy in patients with RSV infection [<xref ref-type="bibr" rid="CR133_21">133</xref>]. Unfortunately, the trial did not enrol a sufficient number of patients to produce conclusions. Intravenous ribavirin has also been evaluated and found unhelpful [<xref ref-type="bibr" rid="CR29_21">29</xref>, <xref ref-type="bibr" rid="CR135_21">135</xref>]. Combining ribavirin with intravenous immunoglobulins or RSV-specific immunoglobulins produced variable levels of efficacy in cohort studies [<xref ref-type="bibr" rid="CR35_21">35</xref>, <xref ref-type="bibr" rid="CR132_21">132</xref>, <xref ref-type="bibr" rid="CR136_21">136</xref>, <xref ref-type="bibr" rid="CR137_21">137</xref>]. Palivizumab, an RSV-specific monoclonal antibody, was evaluated only in a small cohort [<xref ref-type="bibr" rid="CR138_21">138</xref>].</p><p>In vitro, ribavirin exhibits mild antiviral activity against PIV [<xref ref-type="bibr" rid="CR58_21">58</xref>]. No clear efficacy of aerosolized ribavirin was found in small, uncontrolled cohorts of patients with HM [<xref ref-type="bibr" rid="CR34_21">34</xref>, <xref ref-type="bibr" rid="CR139_21">139</xref>]. Early initiation of ribavirin therapy has been proposed to enhance efficacy [<xref ref-type="bibr" rid="CR140_21">140</xref>]. No studies have evaluated intravenous immunoglobulins or RSV-specific immunoglobulins, which contain high titres of PIV-specific immunoglobulins.</p><p>An in vitro study suggests that ribavirin may be of interest for treating human MPV-related pneumonia, but this drug has not been evaluated in patients with HM [<xref ref-type="bibr" rid="CR141_21">141</xref>].</p><p>To date, there is no strong evidence supporting the use of ribavirin, either alone or combined with immunoglobulins, to treat Paramyxoviridae-related pneumonia in patients with HM.</p><p>No controlled randomised study has evaluated the treatment of adenoviral disease in patients with HM. Ribavirin and cidofovir have been suggested for the treatment of adenoviral infections, but only uncontrolled cohort studies are available to support their use. Intravenous ribavirin therapy failed to demonstrate benefits in available studies [<xref ref-type="bibr" rid="CR89_21">89</xref>, <xref ref-type="bibr" rid="CR142_21">142</xref>&#x02013;<xref ref-type="bibr" rid="CR147_21">147</xref>]. Cidofovir therapy (Table <xref rid="Tab3_21" ref-type="table">21.3</xref>) seemed to result in better outcomes in small, uncontrolled series [<xref ref-type="bibr" rid="CR148_21">148</xref>&#x02013;<xref ref-type="bibr" rid="CR153_21">153</xref>]. Ganciclovir and antiretroviral drugs, such as zalcitabine, alovudine, and stavudine, exhibit in vitro activity against adenoviruses, but have not been specifically evaluated in clinical settings [<xref ref-type="bibr" rid="CR95_21">95</xref>, <xref ref-type="bibr" rid="CR154_21">154</xref>]. Considering the lack of specific antiviral drugs, decreasing the level of immunosuppression seems to be a rational treatment approach [<xref ref-type="bibr" rid="CR155_21">155</xref>]. T-cell therapy has also been reported in some small series [<xref ref-type="bibr" rid="CR155_21">155</xref>, <xref ref-type="bibr" rid="CR156_21">156</xref>]. Early cidofovir treatment seems associated with a better outcome [<xref ref-type="bibr" rid="CR151_21">151</xref>]. Weekly PCR screening for adenovirus viraemia has been suggested to guide pre-emptive cidofovir therapy [<xref ref-type="bibr" rid="CR91_21">91</xref>&#x02013;<xref ref-type="bibr" rid="CR94_21">94</xref>, <xref ref-type="bibr" rid="CR153_21">153</xref>, <xref ref-type="bibr" rid="CR157_21">157</xref>]. The exact threshold above which pre-emptive cidofovir therapy should be initiated is unknown. Randomised controlled trials are needed to better define the optimal viraemia threshold for antiviral therapy and to evaluate the benefits from this treatment.</p><p>The greater severity of common respiratory viral infections in HM patients and the lack of clearly proven effective antiviral drugs emphasise the critical importance of preventive strategies.</p></sec></sec><sec id="Sec7_21"><title>Prevention</title><p>The occurrence of common respiratory virus infections in patients with HM is closely related to viral activity in the community. However, nosocomial outbreaks have been described in haematologic wards, often within a few days after an outbreak in the community [<xref ref-type="bibr" rid="CR31_21">31</xref>, <xref ref-type="bibr" rid="CR43_21">43</xref>, <xref ref-type="bibr" rid="CR44_21">44</xref>, <xref ref-type="bibr" rid="CR46_21">46</xref>, <xref ref-type="bibr" rid="CR158_21">158</xref>&#x02013;<xref ref-type="bibr" rid="CR160_21">160</xref>]. Preventing nosocomial transmission of common respiratory viruses requires a multifaceted approach (Table <xref rid="Tab4_21" ref-type="table">21.4</xref>) that targets not only the modes of transmission, but also the source of the viruses [<xref ref-type="bibr" rid="CR43_21">43</xref>]. Nosocomial outbreaks are believed to originate from infected patients and from infected health-care workers. Infection control measures include screening symptomatic patients for common respiratory viruses, early isolation of infected patients, screening health-care workers and visitors for respiratory symptoms, and avoiding contact of symptomatic individuals with patients. Most haematologic wards do not allow children to visit patients, as children are highly prone to common respiratory virus infections and may exhibit viral shedding long after symptom resolution [<xref ref-type="bibr" rid="CR39_21">39</xref>]. Continual reinforcement of standard hygiene measures, especially hand hygiene before and after contact with patients, is also strongly recommended. Awareness of the usefulness of these measures, and therefore adherence to the measures, are low, but can be enhanced by educational programs [<xref ref-type="bibr" rid="CR161_21">161</xref>]. Most of the common respiratory viruses are transmitted by droplets or direct contact of infected secretions with the nasal mucosa or conjunctiva. Indirect transmission via contaminated fomites or devices is also possible, since these viruses may survive several hours on these surfaces [<xref ref-type="bibr" rid="CR6_21">6</xref>, <xref ref-type="bibr" rid="CR7_21">7</xref>, <xref ref-type="bibr" rid="CR58_21">58</xref>]. Consequently, contact isolation of infected patients combined with droplet precautions is mandatory [<xref ref-type="bibr" rid="CR162_21">162</xref>]. A gown, gloves, and a mask with eye protection must be worn for all contacts with infected patients. Airborne transmission of influenza is suspected [<xref ref-type="bibr" rid="CR163_21">163</xref>, <xref ref-type="bibr" rid="CR164_21">164</xref>] but not yet proven, and two recent studies suggest that surgical masks may be as effective in preventing influenza transmission as masks with greater filtration capacity [<xref ref-type="bibr" rid="CR165_21">165</xref>, <xref ref-type="bibr" rid="CR166_21">166</xref>]. Infection control measures have not been evaluated in randomised control trials, but a before-and-after study suggests they may help to prevent the transmission of common respiratory viruses [<xref ref-type="bibr" rid="CR43_21">43</xref>]. It must be pointed out that asymptomatic viral shedding, when present, limits the effectiveness of infection control measures [<xref ref-type="bibr" rid="CR30_21">30</xref>, <xref ref-type="bibr" rid="CR65_21">65</xref>]. The optimal duration of isolation is unknown. Whether isolation should be prolonged in asymptomatic patients with persistent low-titre viral shedding detected only by molecular methods remains unclear. Since adenovirus acquisition is known to result also from endogenous reactivation, adenoviral infections may be chiefly related to the level of immunosuppression [<xref ref-type="bibr" rid="CR39_21">39</xref>, <xref ref-type="bibr" rid="CR86_21">86</xref>] and, therefore, may not be effectively prevented by standard infection control measures.<table-wrap id="Tab4_21"><label>Table 21.4</label><caption><p>Infection control measures for common respiratory viruses</p></caption><table frame="hsides" rules="groups"><tbody><tr><td>Specific infection control measures</td></tr><tr><td>Screening patients for respiratory virus infections</td></tr><tr><td>Contact isolation with droplet precautions for infected patients</td></tr><tr><td>Screening visitors and healthcare workers for URTI symptoms</td></tr><tr><td>Prohibiting visits by individuals with URTI symptoms</td></tr><tr><td>Prohibiting work for healthcare workers with URTI symptoms</td></tr><tr><td>Prohibiting visits by children</td></tr><tr><td>Enhanced standard precautions</td></tr><tr><td>Reinforced hand hygiene before and after contact with patients</td></tr><tr><td>Annual influenza immunisation</td></tr><tr><td>Patients with HM</td></tr><tr><td>Family contacts of patients</td></tr><tr><td>Health-care workers</td></tr></tbody></table></table-wrap>
</p><p>To date, influenza is the only common respiratory virus for which a vaccine is available. Immunisation remains the cornerstone of influenza prevention [<xref ref-type="bibr" rid="CR6_21">6</xref>]. The immunogenicity of the inactivated influenza vaccine is lower in patients with HM compared with immunocompetent controls [<xref ref-type="bibr" rid="CR167_21">167</xref>&#x02013;<xref ref-type="bibr" rid="CR172_21">172</xref>]. A second dose of influenza vaccine has been proposed to enhance immunogenicity, but this strategy was not beneficial in an open-label randomised study [<xref ref-type="bibr" rid="CR169_21">169</xref>, <xref ref-type="bibr" rid="CR170_21">170</xref>]. The timing of influenza immunisation may be important. Immunogenicity may be improved by giving the vaccine at least 6 months after HSCT or at least 7 days after intensive chemotherapy [<xref ref-type="bibr" rid="CR168_21">168</xref>, <xref ref-type="bibr" rid="CR171_21">171</xref>]. The efficacy of influenza immunisation has not been evaluated in randomised control trials. However, a retrospective cohort study suggested benefits from influenza immunisation in HSCT recipients [<xref ref-type="bibr" rid="CR173_21">173</xref>]. Influenza immunisation appears safe in patients with HM, and lifelong seasonal administration of the influenza vaccine is therefore recommended in these high-risk patients [<xref ref-type="bibr" rid="CR174_21">174</xref>]. Importantly, family contacts should be immunised also to prevent transmission within the household. Of critical importance is the issue of health-care worker immunisation, which is known to prevent nosocomial acquisition of the virus [<xref ref-type="bibr" rid="CR175_21">175</xref>].</p><p>Pharmacological interventions have been proposed to prevent common respiratory virus infections. Intravenous immunoglobulins and palivizumab have been suggested for RSV infection prevention, but have not been evaluated in patients with HM. Prophylactic post-exposure oseltamivir therapy is currently recommended in patients with HM [<xref ref-type="bibr" rid="CR176_21">176</xref>]. This preventive measure has not been evaluated in randomised controlled trials, but seems safe based on a recent retrospective study in HSCT recipients [<xref ref-type="bibr" rid="CR177_21">177</xref>]. Considering the lack of proven benefits of oseltamivir therapy and the growing concern about the emergence of oseltamivir-resistant influenza strains, oseltamivir therapy should be carefully evaluated before it is suggested for use on a large scale [<xref ref-type="bibr" rid="CR130_21">130</xref>].</p><p>Another way to prevent morbidity and mortality related to common respiratory viruses in patients with HM is to limit the risk of progression to pneumonia. The pre-emptive treatment of viral URTI has been discussed above. Given the severity of common respiratory virus pneumonia in patients with HM, it appears logical and prudent to postpone HSCT in patients with documented viral infections. A retrospective cohort study suggested that this measure might prevent RSV-related pneumonia in patients undergoing HSCT [<xref ref-type="bibr" rid="CR178_21">178</xref>]. It is unclear whether this measure might be applied to all types of HSCT, to intensive chemotherapy courses, and for all respiratory viruses.</p></sec><sec id="Sec8_21" sec-type="conclusion"><title>Conclusion</title><p>Common respiratory viruses are now recognised as true opportunistic respiratory pathogens in patients with HM. In these patients, they constitute a common cause of potentially severe pneumonia. However, areas of uncertainty remain, indicating a need for further investigations. The epidemiology of common respiratory virus infections in patients with HM has not been extensively studied. Large epidemiological studies of common respiratory virus infections in patients with HM based on molecular biology tools may lead to radical changes in knowledge. Although it is now clear that common respiratory viruses are responsible for increased pneumonia rates in patients with HM, the exact nature and causative mechanisms of these pneumonia cases remain unknown. Studies are warranted to investigate the role of viruses in the development of these LRTIs. The virus might directly injure alveolar epithelium or promote lung super-infection by causing bronchial epithelium damage. These studies would also help to determine the potential benefit of pre-emptive or curative antiviral therapy. Finally, randomised controlled studies of antiviral therapy in patients with HM are urgently needed.</p></sec></body><back><ref-list id="Bib1_21"><title>References</title><ref id="CR1_21"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>File</surname><given-names>TM</given-names></name></person-group><article-title>Community-acquired pneumonia</article-title><source>Lancet</source><year>2003</year><volume>362</volume><issue>9400</issue><fpage>1991</fpage><lpage>2001</lpage><?supplied-pmid 14683661?><pub-id pub-id-type="pmid">14683661</pub-id></element-citation></ref><ref id="CR2_21"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Roux</surname><given-names>A</given-names></name><etal/></person-group><article-title>Viral community-acquired pneumonia in nonimmunocompromised adults</article-title><source>Chest</source><year>2004</year><volume>125</volume><issue>4</issue><fpage>1343</fpage><lpage>1351</lpage><?supplied-pmid 15078744?><pub-id pub-id-type="pmid">15078744</pub-id></element-citation></ref><ref id="CR3_21"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brenner</surname><given-names>H</given-names></name></person-group><article-title>Long-term survival rates of cancer patients achieved by the end of the 20th century: a period analysis</article-title><source>Lancet</source><year>2002</year><volume>360</volume><issue>9340</issue><fpage>1131</fpage><lpage>1135</lpage><?supplied-pmid 12387961?><pub-id pub-id-type="pmid">12387961</pub-id></element-citation></ref><ref id="CR4_21"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Coiffier</surname><given-names>B</given-names></name><etal/></person-group><article-title>CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma</article-title><source>N Engl J Med</source><year>2002</year><volume>346</volume><issue>4</issue><fpage>235</fpage><lpage>242</lpage><?supplied-pmid 11807147?><pub-id pub-id-type="pmid">11807147</pub-id></element-citation></ref><ref id="CR5_21"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nachman</surname><given-names>JB</given-names></name><etal/></person-group><article-title>Augmented post-induction therapy for children with high-risk acute lymphoblastic leukemia and a slow response to initial therapy</article-title><source>N Engl J Med</source><year>1998</year><volume>338</volume><issue>23</issue><fpage>1663</fpage><lpage>1671</lpage><?supplied-pmid 9614257?><pub-id pub-id-type="pmid">9614257</pub-id></element-citation></ref><ref id="CR6_21"><label>6.</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Treanor</surname><given-names>JJ</given-names></name></person-group><person-group person-group-type="editor"><name><surname>Mandell</surname><given-names>G</given-names></name></person-group><article-title>Influenza virus</article-title><source>Principles and practice of infectious diseases</source><year>2005</year><edition>6</edition><publisher-loc>Philadelphia, PA</publisher-loc><publisher-name>Churchill Livingston</publisher-name><fpage>2060</fpage></element-citation></ref><ref id="CR7_21"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hall</surname><given-names>CB</given-names></name></person-group><article-title>Respiratory syncytial virus and parainfluenza virus</article-title><source>N Engl J Med</source><year>2001</year><volume>344</volume><issue>25</issue><fpage>1917</fpage><lpage>1928</lpage><?supplied-pmid 11419430?><pub-id pub-id-type="pmid">11419430</pub-id></element-citation></ref><ref id="CR8_21"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Falsey</surname><given-names>AR</given-names></name><name><surname>Walsh</surname><given-names>EE</given-names></name></person-group><article-title>Respiratory syncytial virus infection in adults</article-title><source>Clin Microbiol Rev</source><year>2000</year><volume>13</volume><issue>3</issue><fpage>371</fpage><lpage>384</lpage><?supplied-pmid 10885982?><pub-id pub-id-type="pmid">10885982</pub-id></element-citation></ref><ref id="CR9_21"><label>9.</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Hall</surname><given-names>CB</given-names></name><name><surname>Mccarthy</surname><given-names>CA</given-names></name></person-group><person-group person-group-type="editor"><name><surname>Mandell</surname><given-names>G</given-names></name></person-group><article-title>Respiratory Syncytial Virus</article-title><source>Principles and practice of infectious diseases</source><year>2005</year><edition>6</edition><publisher-loc>Philadelphia, PA</publisher-loc><publisher-name>Churchill Livingstone</publisher-name><fpage>2008</fpage></element-citation></ref><ref id="CR10_21"><label>10.</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Wright</surname><given-names>PF</given-names></name></person-group><person-group person-group-type="editor"><name><surname>Mandell</surname><given-names>G</given-names></name></person-group><article-title>Parainfluenza viruses</article-title><source>Principles and practice of infectious diseases</source><year>2005</year><edition>6</edition><publisher-loc>Philadelphia, PA</publisher-loc><publisher-name>Churchill Livingstone</publisher-name><fpage>1998</fpage></element-citation></ref><ref id="CR11_21"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van den Hoogen</surname><given-names>BG</given-names></name><etal/></person-group><article-title>A newly discovered human pneumovirus isolated from young children with respiratory tract disease</article-title><source>Nat Med</source><year>2001</year><volume>7</volume><issue>6</issue><fpage>719</fpage><lpage>724</lpage><?supplied-pmid 11385510?><pub-id pub-id-type="pmid">11385510</pub-id></element-citation></ref><ref id="CR12_21"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kahn</surname><given-names>JS</given-names></name></person-group><article-title>Epidemiology of human metapneumovirus</article-title><source>Clin Microbiol Rev</source><year>2006</year><volume>19</volume><issue>3</issue><fpage>546</fpage><lpage>557</lpage><?supplied-pmid 16847085?><pub-id pub-id-type="pmid">16847085</pub-id></element-citation></ref><ref id="CR13_21"><label>13.</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Falsey</surname><given-names>AR</given-names></name></person-group><person-group person-group-type="editor"><name><surname>Mandell</surname><given-names>G</given-names></name></person-group><article-title>Human Metapneumovirus</article-title><source>Principles and practice of infectious diseases</source><year>2005</year><edition>6</edition><publisher-loc>Philadelphia, PA</publisher-loc><publisher-name>Churchill Livingstone</publisher-name><fpage>2027</fpage></element-citation></ref><ref id="CR14_21"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Greenberg</surname><given-names>SB</given-names></name></person-group><article-title>Respiratory consequences of rhinovirus infection</article-title><source>Arch Intern Med</source><year>2003</year><volume>163</volume><issue>3</issue><fpage>278</fpage><lpage>284</lpage><?supplied-pmid 12578507?><pub-id pub-id-type="pmid">12578507</pub-id></element-citation></ref><ref id="CR15_21"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McErlean</surname><given-names>P</given-names></name><etal/></person-group><article-title>Distinguishing molecular features and clinical characteristics of a putative new rhinovirus species, human rhinovirus C (HRV C)</article-title><source>PLoS ONE</source><year>2008</year><volume>3</volume><issue>4</issue><fpage>e1847</fpage><?supplied-pmid 18382652?><pub-id pub-id-type="pmid">18382652</pub-id></element-citation></ref><ref id="CR16_21"><label>16.</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Modlin</surname><given-names>JF</given-names></name></person-group><person-group person-group-type="editor"><name><surname>Mandell</surname><given-names>G</given-names></name></person-group><article-title>Introduction to the Enteroviruses</article-title><source>Principles and practice of infectious diseases</source><year>2005</year><publisher-loc>Philadelphia, PA</publisher-loc><publisher-name>Churchill Livingstone</publisher-name><fpage>2141</fpage></element-citation></ref><ref id="CR17_21"><label>17.</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Stanway</surname><given-names>G</given-names></name></person-group><person-group person-group-type="editor"><name><surname>Fauquet</surname><given-names>CM</given-names></name><name><surname>Mayo</surname><given-names>MA</given-names></name><name><surname>Maniloff</surname><given-names>J</given-names></name><name><surname>Desselberger</surname><given-names>U</given-names></name><name><surname>Ball</surname><given-names>LA</given-names></name></person-group><article-title>Family Picornaviridae</article-title><source>Virus taxonomy. Eighth report of the International Committee on Taxonomy of Viruses</source><year>2005</year><publisher-loc>London</publisher-loc><publisher-name>Elsevier Academic Press</publisher-name><fpage>757</fpage><lpage>778</lpage></element-citation></ref><ref id="CR18_21"><label>18.</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Mcintosh</surname><given-names>K</given-names></name><name><surname>Anderson</surname><given-names>LJ</given-names></name></person-group><person-group person-group-type="editor"><name><surname>Mandell</surname><given-names>G</given-names></name></person-group><article-title>Coronaviruses, Including Severe Acute Respiratory Syndrome (SARS)-Associated Coronavirus</article-title><source>Principles and practice of infectious diseases</source><year>2005</year><edition>6</edition><publisher-loc>Philadelphia, PA</publisher-loc><publisher-name>Churchill Livingstone</publisher-name><fpage>1990</fpage></element-citation></ref><ref id="CR19_21"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kuiken</surname><given-names>T</given-names></name><etal/></person-group><article-title>Newly discovered coronavirus as the primary cause of severe acute respiratory syndrome</article-title><source>Lancet</source><year>2003</year><volume>362</volume><issue>9380</issue><fpage>263</fpage><lpage>270</lpage><?supplied-pmid 12892955?><pub-id pub-id-type="pmid">12892955</pub-id></element-citation></ref><ref id="CR20_21"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van der Hoek</surname><given-names>L</given-names></name><etal/></person-group><article-title>Identification of a new human coronavirus</article-title><source>Nat Med</source><year>2004</year><volume>10</volume><issue>4</issue><fpage>368</fpage><lpage>373</lpage><?supplied-pmid 15034574?><pub-id pub-id-type="pmid">15034574</pub-id></element-citation></ref><ref id="CR21_21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Woo</surname><given-names>PC</given-names></name><etal/></person-group><article-title>Characterization and complete genome sequence of a novel coronavirus, coronavirus HKU1, from patients with pneumonia</article-title><source>J Virol</source><year>2005</year><volume>79</volume><issue>2</issue><fpage>884</fpage><lpage>895</lpage><?supplied-pmid 15613317?><pub-id pub-id-type="pmid">15613317</pub-id></element-citation></ref><ref id="CR22_21"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matthews</surname><given-names>RE</given-names></name></person-group><article-title>The classification and nomenclature of viruses: summary of results of meetings of the International Committee on Taxonomy of Viruses in Strasbourg, August 1981</article-title><source>Intervirology</source><year>1981</year><volume>16</volume><fpage>53</fpage></element-citation></ref><ref id="CR23_21"><label>23.</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Baum</surname><given-names>SG</given-names></name></person-group><person-group person-group-type="editor"><name><surname>Mandell</surname><given-names>G</given-names></name></person-group><article-title>Adenovirus</article-title><source>Principles and practice of infectious diseases</source><year>2005</year><edition>6</edition><publisher-loc>Philadelphia, PA</publisher-loc><publisher-name>Churchill Livingstone</publisher-name><fpage>1624</fpage></element-citation></ref><ref id="CR24_21"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matsuzaki</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Clinical features of influenza C virus infection in children</article-title><source>J Infect Dis</source><year>2006</year><volume>193</volume><issue>9</issue><fpage>1229</fpage><lpage>1235</lpage><?supplied-pmid 16586359?><pub-id pub-id-type="pmid">16586359</pub-id></element-citation></ref><ref id="CR25_21"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Turner</surname><given-names>D</given-names></name><etal/></person-group><article-title>Systematic review and economic decision modelling for the prevention and treatment of influenza A and B</article-title><source>Health Technol Assess</source><year>2003</year><volume>7</volume><issue>35</issue><fpage>iii</fpage><lpage>iv</lpage><?supplied-pmid 14609480?><pub-id pub-id-type="pmid">14609480</pub-id></element-citation></ref><ref id="CR26_21"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dushoff</surname><given-names>J</given-names></name><etal/></person-group><article-title>Mortality due to influenza in the United States &#x02013; an annualized regression approach using multiple-cause mortality data</article-title><source>Am J Epidemiol</source><year>2006</year><volume>163</volume><issue>2</issue><fpage>181</fpage><lpage>187</lpage><?supplied-pmid 16319291?><pub-id pub-id-type="pmid">16319291</pub-id></element-citation></ref><ref id="CR27_21"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dawood</surname><given-names>FS</given-names></name><etal/></person-group><article-title>Emergence of a novel swine-origin influenza A (H1N1) virus in humans</article-title><source>N Engl J Med</source><year>2009</year><volume>360</volume><issue>25</issue><fpage>2605</fpage><lpage>2615</lpage><?supplied-pmid 19423869?><pub-id pub-id-type="pmid">19423869</pub-id></element-citation></ref><ref id="CR28_21"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Falsey</surname><given-names>AR</given-names></name><etal/></person-group><article-title>Respiratory syncytial virus infection in elderly and high-risk adults</article-title><source>N Engl J Med</source><year>2005</year><volume>352</volume><issue>17</issue><fpage>1749</fpage><lpage>1759</lpage><?supplied-pmid 15858184?><pub-id pub-id-type="pmid">15858184</pub-id></element-citation></ref><ref id="CR29_21"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ljungman</surname><given-names>P</given-names></name><etal/></person-group><article-title>Respiratory virus infections after stem cell transplantation: a prospective study from the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation</article-title><source>Bone Marrow Transplant</source><year>2001</year><volume>28</volume><issue>5</issue><fpage>479</fpage><lpage>484</lpage><?supplied-pmid 11593321?><pub-id pub-id-type="pmid">11593321</pub-id></element-citation></ref><ref id="CR30_21"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peck</surname><given-names>AJ</given-names></name><etal/></person-group><article-title>Respiratory virus infection among hematopoietic cell transplant recipients: evidence for asymptomatic parainfluenza virus infection</article-title><source>Blood</source><year>2007</year><volume>110</volume><issue>5</issue><fpage>1681</fpage><lpage>1688</lpage><?supplied-pmid 17502457?><pub-id pub-id-type="pmid">17502457</pub-id></element-citation></ref><ref id="CR31_21"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Couch</surname><given-names>RB</given-names></name><name><surname>Englund</surname><given-names>JA</given-names></name><name><surname>Whimbey</surname><given-names>E</given-names></name></person-group><article-title>Respiratory viral infections in immunocompetent and immunocompromised persons</article-title><source>Am J Med</source><year>1997</year><volume>102</volume><issue>3A</issue><fpage>2</fpage><lpage>9</lpage><?supplied-pmid 10868136?><pub-id pub-id-type="pmid">10868136</pub-id></element-citation></ref><ref id="CR32_21"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martino</surname><given-names>R</given-names></name><etal/></person-group><article-title>Respiratory virus infections in adults with hematologic malignancies: a prospective study</article-title><source>Clin Infect Dis</source><year>2003</year><volume>36</volume><issue>1</issue><fpage>1</fpage><lpage>8</lpage><?supplied-pmid 12491194?><pub-id pub-id-type="pmid">12491194</pub-id></element-citation></ref><ref id="CR33_21"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nichols</surname><given-names>WG</given-names></name><etal/></person-group><article-title>Influenza infections after hematopoietic stem cell transplantation: risk factors, mortality, and the effect of antiviral therapy</article-title><source>Clin Infect Dis</source><year>2004</year><volume>39</volume><issue>9</issue><fpage>1300</fpage><lpage>1306</lpage><?supplied-pmid 15494906?><pub-id pub-id-type="pmid">15494906</pub-id></element-citation></ref><ref id="CR34_21"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chemaly</surname><given-names>RF</given-names></name><etal/></person-group><article-title>Respiratory viral infections in adults with hematologic malignancies and human stem cell transplantation recipients: a retrospective study at a major cancer center</article-title><source>Medicine (Baltimore)</source><year>2006</year><volume>85</volume><issue>5</issue><fpage>278</fpage><lpage>287</lpage><pub-id pub-id-type="pmid">16974212</pub-id></element-citation></ref><ref id="CR35_21"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Machado</surname><given-names>CM</given-names></name><etal/></person-group><article-title>Low mortality rates related to respiratory virus infections after bone marrow transplantation</article-title><source>Bone Marrow Transplant</source><year>2003</year><volume>31</volume><issue>8</issue><fpage>695</fpage><lpage>700</lpage><?supplied-pmid 12692610?><pub-id pub-id-type="pmid">12692610</pub-id></element-citation></ref><ref id="CR36_21"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martino</surname><given-names>R</given-names></name><etal/></person-group><article-title>Prospective study of the incidence, clinical features, and outcome of symptomatic upper and lower respiratory tract infections by respiratory viruses in adult recipients of hematopoietic stem cell transplants for hematologic malignancies</article-title><source>Biol Blood Marrow Transplant</source><year>2005</year><volume>11</volume><issue>10</issue><fpage>781</fpage><lpage>796</lpage><?supplied-pmid 16182179?><pub-id pub-id-type="pmid">16182179</pub-id></element-citation></ref><ref id="CR37_21"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kolavic-Gray</surname><given-names>SA</given-names></name><etal/></person-group><article-title>Large epidemic of adenovirus type 4 infection among military trainees: epidemiological, clinical, and laboratory studies</article-title><source>Clin Infect Dis</source><year>2002</year><volume>35</volume><issue>7</issue><fpage>808</fpage><lpage>818</lpage><?supplied-pmid 12228817?><pub-id pub-id-type="pmid">12228817</pub-id></element-citation></ref><ref id="CR38_21"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ryan</surname><given-names>MA</given-names></name><etal/></person-group><article-title>Large epidemic of respiratory illness due to adenovirus types 7 and 3 in healthy young adults</article-title><source>Clin Infect Dis</source><year>2002</year><volume>34</volume><issue>5</issue><fpage>577</fpage><lpage>582</lpage><?supplied-pmid 11803503?><pub-id pub-id-type="pmid">11803503</pub-id></element-citation></ref><ref id="CR39_21"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boeckh</surname><given-names>M</given-names></name></person-group><article-title>The challenge of respiratory virus infections in hematopoietic cell transplant recipients</article-title><source>Br J Haematol</source><year>2008</year><volume>143</volume><issue>4</issue><fpage>455</fpage><lpage>467</lpage><?supplied-pmid 18785968?><pub-id pub-id-type="pmid">18785968</pub-id></element-citation></ref><ref id="CR40_21"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chien</surname><given-names>JW</given-names></name><etal/></person-group><article-title>Airflow obstruction after myeloablative allogeneic hematopoietic stem cell transplantation</article-title><source>Am J Respir Crit Care Med</source><year>2003</year><volume>168</volume><issue>2</issue><fpage>208</fpage><lpage>214</lpage><?supplied-pmid 12649126?><pub-id pub-id-type="pmid">12649126</pub-id></element-citation></ref><ref id="CR41_21"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boivin</surname><given-names>G</given-names></name><name><surname>Goyette</surname><given-names>N</given-names></name><name><surname>Bernatchez</surname><given-names>H</given-names></name></person-group><article-title>Prolonged excretion of amantadine-resistant influenza a virus quasi species after cessation of antiviral therapy in an immunocompromised patient</article-title><source>Clin Infect Dis</source><year>2002</year><volume>34</volume><issue>5</issue><fpage>E23</fpage><lpage>E25</lpage><?supplied-pmid 11807683?><pub-id pub-id-type="pmid">11807683</pub-id></element-citation></ref><ref id="CR42_21"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weinstock</surname><given-names>DM</given-names></name><name><surname>Gubareva</surname><given-names>LV</given-names></name><name><surname>Zuccotti</surname><given-names>G</given-names></name></person-group><article-title>Prolonged shedding of multidrug-resistant influenza A virus in an immunocompromised patient</article-title><source>N Engl J Med</source><year>2003</year><volume>348</volume><issue>9</issue><fpage>867</fpage><lpage>868</lpage><?supplied-pmid 12606750?><pub-id pub-id-type="pmid">12606750</pub-id></element-citation></ref><ref id="CR43_21"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Raad</surname><given-names>I</given-names></name><name><surname>Abbas</surname><given-names>J</given-names></name><name><surname>Whimbey</surname><given-names>E</given-names></name></person-group><article-title>Infection control of nosocomial respiratory viral disease in the immunocompromised host</article-title><source>Am J Med</source><year>1997</year><volume>102</volume><issue>3A</issue><fpage>48</fpage><lpage>52</lpage><?supplied-pmid 10868143?><pub-id pub-id-type="pmid">10868143</pub-id></element-citation></ref><ref id="CR44_21"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zambon</surname><given-names>M</given-names></name><etal/></person-group><article-title>Molecular epidemiology of two consecutive outbreaks of parainfluenza 3 in a bone marrow transplant unit</article-title><source>J Clin Microbiol</source><year>1998</year><volume>36</volume><issue>8</issue><fpage>2289</fpage><lpage>2293</lpage><?supplied-pmid 9666007?><pub-id pub-id-type="pmid">9666007</pub-id></element-citation></ref><ref id="CR45_21"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Elting</surname><given-names>LS</given-names></name><etal/></person-group><article-title>Epidemiology of influenza A virus infection in patients with acute or chronic leukemia</article-title><source>Support Care Cancer</source><year>1995</year><volume>3</volume><issue>3</issue><fpage>198</fpage><lpage>202</lpage><?supplied-pmid 7655781?><pub-id pub-id-type="pmid">7655781</pub-id></element-citation></ref><ref id="CR46_21"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Harrington</surname><given-names>RD</given-names></name><etal/></person-group><article-title>An outbreak of respiratory syncytial virus in a bone marrow transplant center</article-title><source>J Infect Dis</source><year>1992</year><volume>165</volume><issue>6</issue><fpage>987</fpage><lpage>993</lpage><?supplied-pmid 1583345?><pub-id pub-id-type="pmid">1583345</pub-id></element-citation></ref><ref id="CR47_21"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khanna</surname><given-names>N</given-names></name><etal/></person-group><article-title>Respiratory syncytial virus infection in patients with hematological diseases: single-center study and review of the literature</article-title><source>Clin Infect Dis</source><year>2008</year><volume>46</volume><issue>3</issue><fpage>402</fpage><lpage>412</lpage><?supplied-pmid 18181739?><pub-id pub-id-type="pmid">18181739</pub-id></element-citation></ref><ref id="CR48_21"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Whimbey</surname><given-names>E</given-names></name><etal/></person-group><article-title>Respiratory syncytial virus pneumonia in hospitalized adult patients with leukemia</article-title><source>Clin Infect Dis</source><year>1995</year><volume>21</volume><issue>2</issue><fpage>376</fpage><lpage>379</lpage><?supplied-pmid 8562747?><pub-id pub-id-type="pmid">8562747</pub-id></element-citation></ref><ref id="CR49_21"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Whimbey</surname><given-names>E</given-names></name><etal/></person-group><article-title>Influenza A virus infections among hospitalized adult bone marrow transplant recipients</article-title><source>Bone Marrow Transplant</source><year>1994</year><volume>13</volume><issue>4</issue><fpage>437</fpage><lpage>440</lpage><?supplied-pmid 8019468?><pub-id pub-id-type="pmid">8019468</pub-id></element-citation></ref><ref id="CR50_21"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yousuf</surname><given-names>HM</given-names></name><etal/></person-group><article-title>Influenza among hospitalized adults with leukemia</article-title><source>Clin Infect Dis</source><year>1997</year><volume>24</volume><issue>6</issue><fpage>1095</fpage><lpage>1099</lpage><?supplied-pmid 9195063?><pub-id pub-id-type="pmid">9195063</pub-id></element-citation></ref><ref id="CR51_21"><label>51.</label><mixed-citation publication-type="other">Ladisla B (1996) Community respiratory virus infections in hospitalized adult patients with leukemia. In: Abstract of the Infectious Diseases Society of America, 1996, New Orleans, Louisiana, p. Abstract No. 99</mixed-citation></ref><ref id="CR52_21"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Whimbey</surname><given-names>E</given-names></name><etal/></person-group><article-title>Community respiratory virus infections among hospitalized adult bone marrow transplant recipients</article-title><source>Clin Infect Dis</source><year>1996</year><volume>22</volume><issue>5</issue><fpage>778</fpage><lpage>782</lpage><?supplied-pmid 8722930?><pub-id pub-id-type="pmid">8722930</pub-id></element-citation></ref><ref id="CR53_21"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Whimbey</surname><given-names>E</given-names></name><name><surname>Englund</surname><given-names>JA</given-names></name><name><surname>Couch</surname><given-names>RB</given-names></name></person-group><article-title>Community respiratory virus infections in immunocompromised patients with cancer</article-title><source>Am J Med</source><year>1997</year><volume>102</volume><issue>3A</issue><fpage>10</fpage><lpage>18</lpage><?supplied-pmid 10868137?><pub-id pub-id-type="pmid">10868137</pub-id></element-citation></ref><ref id="CR54_21"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sivadon-Tardy</surname><given-names>V</given-names></name><etal/></person-group><article-title>Guillain-Barre syndrome and influenza virus infection</article-title><source>Clin Infect Dis</source><year>2009</year><volume>48</volume><issue>1</issue><fpage>48</fpage><lpage>56</lpage><?supplied-pmid 19025491?><pub-id pub-id-type="pmid">19025491</pub-id></element-citation></ref><ref id="CR55_21"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Falsey</surname><given-names>AR</given-names></name><etal/></person-group><article-title>Respiratory syncytial virus and influenza A infections in the hospitalized elderly</article-title><source>J Infect Dis</source><year>1995</year><volume>172</volume><issue>2</issue><fpage>389</fpage><lpage>394</lpage><?supplied-pmid 7622882?><pub-id pub-id-type="pmid">7622882</pub-id></element-citation></ref><ref id="CR56_21"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yui</surname><given-names>I</given-names></name><etal/></person-group><article-title>Detection of human respiratory syncytial virus sequences in peripheral blood mononuclear cells</article-title><source>J Med Virol</source><year>2003</year><volume>70</volume><issue>3</issue><fpage>481</fpage><lpage>489</lpage><?supplied-pmid 12767015?><pub-id pub-id-type="pmid">12767015</pub-id></element-citation></ref><ref id="CR57_21"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nichols</surname><given-names>WG</given-names></name><name><surname>Gooley</surname><given-names>T</given-names></name><name><surname>Boeckh</surname><given-names>M</given-names></name></person-group><article-title>Community-acquired respiratory syncytial virus and parainfluenza virus infections after hematopoietic stem cell transplantation: the Fred Hutchinson Cancer Research Center experience</article-title><source>Biol Blood Marrow Transplant</source><year>2001</year><volume>7</volume><issue>Suppl</issue><fpage>11S</fpage><lpage>15S</lpage><?supplied-pmid 11777098?><pub-id pub-id-type="pmid">11777098</pub-id></element-citation></ref><ref id="CR58_21"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Henrickson</surname><given-names>KJ</given-names></name></person-group><article-title>Parainfluenza viruses</article-title><source>Clin Microbiol Rev</source><year>2003</year><volume>16</volume><issue>2</issue><fpage>242</fpage><lpage>264</lpage><?supplied-pmid 12692097?><pub-id pub-id-type="pmid">12692097</pub-id></element-citation></ref><ref id="CR59_21"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cane</surname><given-names>PA</given-names></name><etal/></person-group><article-title>Human metapneumovirus in a haematopoietic stem cell transplant recipient with fatal lower respiratory tract disease</article-title><source>Bone Marrow Transplant</source><year>2003</year><volume>31</volume><issue>4</issue><fpage>309</fpage><lpage>310</lpage><?supplied-pmid 12621469?><pub-id pub-id-type="pmid">12621469</pub-id></element-citation></ref><ref id="CR60_21"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Englund</surname><given-names>JA</given-names></name><etal/></person-group><article-title>Brief communication: fatal human metapneumovirus infection in stem-cell transplant recipients</article-title><source>Ann Intern Med</source><year>2006</year><volume>144</volume><issue>5</issue><fpage>344</fpage><lpage>349</lpage><?supplied-pmid 16520475?><pub-id pub-id-type="pmid">16520475</pub-id></element-citation></ref><ref id="CR61_21"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pelletier</surname><given-names>G</given-names></name><etal/></person-group><article-title>Respiratory tract reinfections by the new human Metapneumovirus in an immunocompromised child</article-title><source>Emerg Infect Dis</source><year>2002</year><volume>8</volume><issue>9</issue><fpage>976</fpage><lpage>978</lpage><?supplied-pmid 12194777?><pub-id pub-id-type="pmid">12194777</pub-id></element-citation></ref><ref id="CR62_21"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kamboj</surname><given-names>M</given-names></name><etal/></person-group><article-title>Clinical characterization of human metapneumovirus infection among patients with cancer</article-title><source>J Infect</source><year>2008</year><volume>57</volume><issue>6</issue><fpage>464</fpage><lpage>471</lpage><?supplied-pmid 19027169?><pub-id pub-id-type="pmid">19027169</pub-id></element-citation></ref><ref id="CR63_21"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oliveira</surname><given-names>R</given-names></name><etal/></person-group><article-title>Frequency of human metapneumovirus infection in hematopoietic SCT recipients during 3 consecutive years</article-title><source>Bone Marrow Transplant</source><year>2008</year><volume>42</volume><issue>4</issue><fpage>265</fpage><lpage>269</lpage><?supplied-pmid 18516078?><pub-id pub-id-type="pmid">18516078</pub-id></element-citation></ref><ref id="CR64_21"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Williams</surname><given-names>JV</given-names></name><etal/></person-group><article-title>A prospective study comparing human metapneumovirus with other respiratory viruses in adults with hematologic malignancies and respiratory tract infections</article-title><source>J Infect Dis</source><year>2005</year><volume>192</volume><issue>6</issue><fpage>1061</fpage><lpage>1065</lpage><?supplied-pmid 16107960?><pub-id pub-id-type="pmid">16107960</pub-id></element-citation></ref><ref id="CR65_21"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Debiaggi</surname><given-names>M</given-names></name><etal/></person-group><article-title>Long-term study on symptomless human metapneumovirus infection in hematopoietic stem cell transplant recipients</article-title><source>New Microbiol</source><year>2007</year><volume>30</volume><issue>3</issue><fpage>255</fpage><lpage>258</lpage><?supplied-pmid 17802904?><pub-id pub-id-type="pmid">17802904</pub-id></element-citation></ref><ref id="CR66_21"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kaida</surname><given-names>A</given-names></name><etal/></person-group><article-title>Seasonal distribution and phylogenetic analysis of human metapneumovirus among children in Osaka City, Japan</article-title><source>J Clin Virol</source><year>2006</year><volume>35</volume><issue>4</issue><fpage>394</fpage><lpage>399</lpage><?supplied-pmid 16460998?><pub-id pub-id-type="pmid">16460998</pub-id></element-citation></ref><ref id="CR67_21"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schildgen</surname><given-names>O</given-names></name><etal/></person-group><article-title>Human metapneumovirus RNA in encephalitis patient</article-title><source>Emerg Infect Dis</source><year>2005</year><volume>11</volume><issue>3</issue><fpage>467</fpage><lpage>470</lpage><?supplied-pmid 15757568?><pub-id pub-id-type="pmid">15757568</pub-id></element-citation></ref><ref id="CR68_21"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nicholson</surname><given-names>KG</given-names></name><etal/></person-group><article-title>Risk factors for lower respiratory complications of rhinovirus infections in elderly people living in the community: prospective cohort study</article-title><source>BMJ</source><year>1996</year><volume>313</volume><issue>7065</issue><fpage>1119</fpage><lpage>1123</lpage><?supplied-pmid 8916700?><pub-id pub-id-type="pmid">8916700</pub-id></element-citation></ref><ref id="CR69_21"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Papadopoulos</surname><given-names>NG</given-names></name></person-group><article-title>Do rhinoviruses cause pneumonia in children?</article-title><source>Paediatr Respir Rev</source><year>2004</year><volume>5</volume><issue>Suppl A</issue><fpage>S191</fpage><lpage>S195</lpage><?supplied-pmid 14980269?><pub-id pub-id-type="pmid">14980269</pub-id></element-citation></ref><ref id="CR70_21"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hayden</surname><given-names>FG</given-names></name></person-group><article-title>Rhinovirus and the lower respiratory tract</article-title><source>Rev Med Virol</source><year>2004</year><volume>14</volume><issue>1</issue><fpage>17</fpage><lpage>31</lpage><?supplied-pmid 14716689?><pub-id pub-id-type="pmid">14716689</pub-id></element-citation></ref><ref id="CR71_21"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Papadopoulos</surname><given-names>NG</given-names></name><etal/></person-group><article-title>Rhinoviruses infect the lower airways</article-title><source>J Infect Dis</source><year>2000</year><volume>181</volume><issue>6</issue><fpage>1875</fpage><lpage>1884</lpage><?supplied-pmid 10837165?><pub-id pub-id-type="pmid">10837165</pub-id></element-citation></ref><ref id="CR72_21"><label>72.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kaiser</surname><given-names>L</given-names></name><name><surname>Hayden</surname><given-names>FG</given-names></name></person-group><article-title>Editorial response: rhinovirus pneumonia&#x02013;a clinical entity?</article-title><source>Clin Infect Dis</source><year>1999</year><volume>29</volume><issue>3</issue><fpage>533</fpage><lpage>535</lpage><?supplied-pmid 10530442?><pub-id pub-id-type="pmid">10530442</pub-id></element-citation></ref><ref id="CR73_21"><label>73.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ghosh</surname><given-names>S</given-names></name><etal/></person-group><article-title>Rhinovirus infections in myelosuppressed adult blood and marrow transplant recipients</article-title><source>Clin Infect Dis</source><year>1999</year><volume>29</volume><issue>3</issue><fpage>528</fpage><lpage>532</lpage><?supplied-pmid 10530441?><pub-id pub-id-type="pmid">10530441</pub-id></element-citation></ref><ref id="CR74_21"><label>74.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gutman</surname><given-names>JA</given-names></name><etal/></person-group><article-title>Rhinovirus as a cause of fatal lower respiratory tract infection in adult stem cell transplantation patients: a report of two cases</article-title><source>Bone Marrow Transplant</source><year>2007</year><volume>40</volume><issue>8</issue><fpage>809</fpage><lpage>811</lpage><?supplied-pmid 17704788?><pub-id pub-id-type="pmid">17704788</pub-id></element-citation></ref><ref id="CR75_21"><label>75.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Imakita</surname><given-names>M</given-names></name><etal/></person-group><article-title>Pneumonia caused by rhinovirus</article-title><source>Clin Infect Dis</source><year>2000</year><volume>30</volume><issue>3</issue><fpage>611</fpage><lpage>612</lpage><?supplied-pmid 10722460?><pub-id pub-id-type="pmid">10722460</pub-id></element-citation></ref><ref id="CR76_21"><label>76.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ison</surname><given-names>MG</given-names></name><etal/></person-group><article-title>Rhinovirus infections in hematopoietic stem cell transplant recipients with pneumonia</article-title><source>Clin Infect Dis</source><year>2003</year><volume>36</volume><issue>9</issue><fpage>1139</fpage><lpage>1143</lpage><?supplied-pmid 12715308?><pub-id pub-id-type="pmid">12715308</pub-id></element-citation></ref><ref id="CR77_21"><label>77.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Parody</surname><given-names>R</given-names></name><etal/></person-group><article-title>Upper and lower respiratory tract infections by human enterovirus and rhinovirus in adult patients with hematological malignancies</article-title><source>Am J Hematol</source><year>2007</year><volume>82</volume><issue>9</issue><fpage>807</fpage><lpage>811</lpage><?supplied-pmid 17563077?><pub-id pub-id-type="pmid">17563077</pub-id></element-citation></ref><ref id="CR78_21"><label>78.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gonzalez</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Pulmonary enterovirus infections in stem cell transplant recipients</article-title><source>Bone Marrow Transplant</source><year>1999</year><volume>23</volume><issue>5</issue><fpage>511</fpage><lpage>513</lpage><?supplied-pmid 10100567?><pub-id pub-id-type="pmid">10100567</pub-id></element-citation></ref><ref id="CR79_21"><label>79.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gonzalez</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Community respiratory virus infections in patients with hematologic malignancies</article-title><source>Haematologica</source><year>1999</year><volume>84</volume><issue>9</issue><fpage>820</fpage><lpage>823</lpage><?supplied-pmid 10477456?><pub-id pub-id-type="pmid">10477456</pub-id></element-citation></ref><ref id="CR80_21"><label>80.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rabella</surname><given-names>N</given-names></name><etal/></person-group><article-title>Conventional respiratory viruses recovered from immunocompromised patients: clinical considerations</article-title><source>Clin Infect Dis</source><year>1999</year><volume>28</volume><issue>5</issue><fpage>1043</fpage><lpage>1048</lpage><?supplied-pmid 10452632?><pub-id pub-id-type="pmid">10452632</pub-id></element-citation></ref><ref id="CR81_21"><label>81.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kahn</surname><given-names>JS</given-names></name><name><surname>McIntosh</surname><given-names>K</given-names></name></person-group><article-title>History and recent advances in coronavirus discovery</article-title><source>Pediatr Infect Dis J</source><year>2005</year><volume>24</volume><issue>11 Suppl</issue><fpage>S223</fpage><lpage>S227</lpage><?supplied-pmid 16378050?><pub-id pub-id-type="pmid">16378050</pub-id></element-citation></ref><ref id="CR82_21"><label>82.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Folz</surname><given-names>RJ</given-names></name><name><surname>Elkordy</surname><given-names>MA</given-names></name></person-group><article-title>Coronavirus pneumonia following autologous bone marrow transplantation for breast cancer</article-title><source>Chest</source><year>1999</year><volume>115</volume><issue>3</issue><fpage>901</fpage><lpage>905</lpage><?supplied-pmid 10084516?><pub-id pub-id-type="pmid">10084516</pub-id></element-citation></ref><ref id="CR83_21"><label>83.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pene</surname><given-names>F</given-names></name><etal/></person-group><article-title>Coronavirus 229E-related pneumonia in immunocompromised patients</article-title><source>Clin Infect Dis</source><year>2003</year><volume>37</volume><issue>7</issue><fpage>929</fpage><lpage>932</lpage><?supplied-pmid 13130404?><pub-id pub-id-type="pmid">13130404</pub-id></element-citation></ref><ref id="CR84_21"><label>84.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Erard</surname><given-names>V</given-names></name><etal/></person-group><article-title>Airflow decline after myeloablative allogeneic hematopoietic cell transplantation: the role of community respiratory viruses</article-title><source>J Infect Dis</source><year>2006</year><volume>193</volume><issue>12</issue><fpage>1619</fpage><lpage>1625</lpage><?supplied-pmid 16703503?><pub-id pub-id-type="pmid">16703503</pub-id></element-citation></ref><ref id="CR85_21"><label>85.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Walter</surname><given-names>MJ</given-names></name><etal/></person-group><article-title>Viral induction of a chronic asthma phenotype and genetic segregation from the acute response</article-title><source>J Clin Invest</source><year>2002</year><volume>110</volume><issue>2</issue><fpage>165</fpage><lpage>175</lpage><?supplied-pmid 12122108?><pub-id pub-id-type="pmid">12122108</pub-id></element-citation></ref><ref id="CR86_21"><label>86.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chakrabarti</surname><given-names>S</given-names></name><etal/></person-group><article-title>Adenovirus infections following allogeneic stem cell transplantation: incidence and outcome in relation to graft manipulation, immunosuppression, and immune recovery</article-title><source>Blood</source><year>2002</year><volume>100</volume><issue>5</issue><fpage>1619</fpage><lpage>1627</lpage><?supplied-pmid 12176880?><pub-id pub-id-type="pmid">12176880</pub-id></element-citation></ref><ref id="CR87_21"><label>87.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Flomenberg</surname><given-names>P</given-names></name><etal/></person-group><article-title>Increasing incidence of adenovirus disease in bone marrow transplant recipients</article-title><source>J Infect Dis</source><year>1994</year><volume>169</volume><issue>4</issue><fpage>775</fpage><lpage>781</lpage><?supplied-pmid 8133091?><pub-id pub-id-type="pmid">8133091</pub-id></element-citation></ref><ref id="CR88_21"><label>88.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Howard</surname><given-names>DS</given-names></name><etal/></person-group><article-title>Adenovirus infections in hematopoietic stem cell transplant recipients</article-title><source>Clin Infect Dis</source><year>1999</year><volume>29</volume><issue>6</issue><fpage>1494</fpage><lpage>1501</lpage><?supplied-pmid 10585802?><pub-id pub-id-type="pmid">10585802</pub-id></element-citation></ref><ref id="CR89_21"><label>89.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>La Rosa</surname><given-names>AM</given-names></name><etal/></person-group><article-title>Adenovirus infections in adult recipients of blood and marrow transplants</article-title><source>Clin Infect Dis</source><year>2001</year><volume>32</volume><issue>6</issue><fpage>871</fpage><lpage>876</lpage><?supplied-pmid 11247710?><pub-id pub-id-type="pmid">11247710</pub-id></element-citation></ref><ref id="CR90_21"><label>90.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baldwin</surname><given-names>A</given-names></name><etal/></person-group><article-title>Outcome and clinical course of 100 patients with adenovirus infection following bone marrow transplantation</article-title><source>Bone Marrow Transplant</source><year>2000</year><volume>26</volume><issue>12</issue><fpage>1333</fpage><lpage>1338</lpage><?supplied-pmid 11223974?><pub-id pub-id-type="pmid">11223974</pub-id></element-citation></ref><ref id="CR91_21"><label>91.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lion</surname><given-names>T</given-names></name><etal/></person-group><article-title>Molecular monitoring of adenovirus in peripheral blood after allogeneic bone marrow transplantation permits early diagnosis of disseminated disease</article-title><source>Blood</source><year>2003</year><volume>102</volume><issue>3</issue><fpage>1114</fpage><lpage>1120</lpage><?supplied-pmid 12702513?><pub-id pub-id-type="pmid">12702513</pub-id></element-citation></ref><ref id="CR92_21"><label>92.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Echavarria</surname><given-names>M</given-names></name><etal/></person-group><article-title>Prediction of severe disseminated adenovirus infection by serum PCR</article-title><source>Lancet</source><year>2001</year><volume>358</volume><issue>9279</issue><fpage>384</fpage><lpage>385</lpage><?supplied-pmid 11502321?><pub-id pub-id-type="pmid">11502321</pub-id></element-citation></ref><ref id="CR93_21"><label>93.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Erard</surname><given-names>V</given-names></name><etal/></person-group><article-title>Quantitative real-time polymerase chain reaction for detection of adenovirus after T cell-replete hematopoietic cell transplantation: viral load as a marker for invasive disease</article-title><source>Clin Infect Dis</source><year>2007</year><volume>45</volume><issue>8</issue><fpage>958</fpage><lpage>965</lpage><?supplied-pmid 17879908?><pub-id pub-id-type="pmid">17879908</pub-id></element-citation></ref><ref id="CR94_21"><label>94.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schilham</surname><given-names>MW</given-names></name><etal/></person-group><article-title>High levels of adenovirus DNA in serum correlate with fatal outcome of adenovirus infection in children after allogeneic stem-cell transplantation</article-title><source>Clin Infect Dis</source><year>2002</year><volume>35</volume><issue>5</issue><fpage>526</fpage><lpage>532</lpage><?supplied-pmid 12173125?><pub-id pub-id-type="pmid">12173125</pub-id></element-citation></ref><ref id="CR95_21"><label>95.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bruno</surname><given-names>B</given-names></name><etal/></person-group><article-title>Adenovirus infection in hematopoietic stem cell transplantation: effect of ganciclovir and impact on survival</article-title><source>Biol Blood Marrow Transplant</source><year>2003</year><volume>9</volume><issue>5</issue><fpage>341</fpage><lpage>352</lpage><?supplied-pmid 12766884?><pub-id pub-id-type="pmid">12766884</pub-id></element-citation></ref><ref id="CR96_21"><label>96.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hale</surname><given-names>GA</given-names></name><etal/></person-group><article-title>Adenovirus infection after pediatric bone marrow transplantation</article-title><source>Bone Marrow Transplant</source><year>1999</year><volume>23</volume><issue>3</issue><fpage>277</fpage><lpage>282</lpage><?supplied-pmid 10084260?><pub-id pub-id-type="pmid">10084260</pub-id></element-citation></ref><ref id="CR97_21"><label>97.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bruno</surname><given-names>B</given-names></name><etal/></person-group><article-title>Adenovirus nephritis in hematopoietic stem-cell transplantation</article-title><source>Transplantation</source><year>2004</year><volume>77</volume><issue>7</issue><fpage>1049</fpage><lpage>1057</lpage><?supplied-pmid 15087771?><pub-id pub-id-type="pmid">15087771</pub-id></element-citation></ref><ref id="CR98_21"><label>98.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cox</surname><given-names>GJ</given-names></name><etal/></person-group><article-title>Etiology and outcome of diarrhea after marrow transplantation: a prospective study</article-title><source>Gastroenterology</source><year>1994</year><volume>107</volume><issue>5</issue><fpage>1398</fpage><lpage>1407</lpage><?supplied-pmid 7926504?><pub-id pub-id-type="pmid">7926504</pub-id></element-citation></ref><ref id="CR99_21"><label>99.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Glezen</surname><given-names>WP</given-names></name><etal/></person-group><article-title>Impact of respiratory virus infections on persons with chronic underlying conditions</article-title><source>JAMA</source><year>2000</year><volume>283</volume><issue>4</issue><fpage>499</fpage><lpage>505</lpage><?supplied-pmid 10659876?><pub-id pub-id-type="pmid">10659876</pub-id></element-citation></ref><ref id="CR100_21"><label>100.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barenfanger</surname><given-names>J</given-names></name><etal/></person-group><article-title>Clinical and financial benefits of rapid detection of respiratory viruses: an outcomes study</article-title><source>J Clin Microbiol</source><year>2000</year><volume>38</volume><issue>8</issue><fpage>2824</fpage><lpage>2828</lpage><?supplied-pmid 10921934?><pub-id pub-id-type="pmid">10921934</pub-id></element-citation></ref><ref id="CR101_21"><label>101.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Woo</surname><given-names>PC</given-names></name><etal/></person-group><article-title>Cost-effectiveness of rapid diagnosis of viral respiratory tract infections in pediatric patients</article-title><source>J Clin Microbiol</source><year>1997</year><volume>35</volume><issue>6</issue><fpage>1579</fpage><lpage>1581</lpage><?supplied-pmid 9163486?><pub-id pub-id-type="pmid">9163486</pub-id></element-citation></ref><ref id="CR102_21"><label>102.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Singh-Naz</surname><given-names>N</given-names></name><name><surname>Brown</surname><given-names>M</given-names></name><name><surname>Ganeshananthan</surname><given-names>M</given-names></name></person-group><article-title>Nosocomial adenovirus infection: molecular epidemiology of an outbreak</article-title><source>Pediatr Infect Dis J</source><year>1993</year><volume>12</volume><issue>11</issue><fpage>922</fpage><lpage>925</lpage><?supplied-pmid 8265282?><pub-id pub-id-type="pmid">8265282</pub-id></element-citation></ref><ref id="CR103_21"><label>103.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heikkinen</surname><given-names>T</given-names></name><etal/></person-group><article-title>Nasal swab versus nasopharyngeal aspirate for isolation of respiratory viruses</article-title><source>J Clin Microbiol</source><year>2002</year><volume>40</volume><issue>11</issue><fpage>4337</fpage><lpage>4339</lpage><?supplied-pmid 12409425?><pub-id pub-id-type="pmid">12409425</pub-id></element-citation></ref><ref id="CR104_21"><label>104.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stensballe</surname><given-names>LG</given-names></name><etal/></person-group><article-title>Comparison of nasopharyngeal aspirate and nasal swab specimens for detection of respiratory syncytial virus in different settings in a developing country</article-title><source>Trop Med Int Health</source><year>2002</year><volume>7</volume><issue>4</issue><fpage>317</fpage><lpage>321</lpage><?supplied-pmid 11952947?><pub-id pub-id-type="pmid">11952947</pub-id></element-citation></ref><ref id="CR105_21"><label>105.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abu-Diab</surname><given-names>A</given-names></name><etal/></person-group><article-title>Comparison between pernasal flocked swabs and nasopharyngeal aspirates for detection of common respiratory viruses in samples from children</article-title><source>J Clin Microbiol</source><year>2008</year><volume>46</volume><issue>7</issue><fpage>2414</fpage><lpage>2417</lpage><?supplied-pmid 18480225?><pub-id pub-id-type="pmid">18480225</pub-id></element-citation></ref><ref id="CR106_21"><label>106.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Daley</surname><given-names>P</given-names></name><etal/></person-group><article-title>Comparison of flocked and rayon swabs for collection of respiratory epithelial cells from uninfected volunteers and symptomatic patients</article-title><source>J Clin Microbiol</source><year>2006</year><volume>44</volume><issue>6</issue><fpage>2265</fpage><lpage>2267</lpage><?supplied-pmid 16757636?><pub-id pub-id-type="pmid">16757636</pub-id></element-citation></ref><ref id="CR107_21"><label>107.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gunson</surname><given-names>RN</given-names></name><name><surname>Collins</surname><given-names>TC</given-names></name><name><surname>Carman</surname><given-names>WF</given-names></name></person-group><article-title>Real-time RT-PCR detection of 12 respiratory viral infections in four triplex reactions</article-title><source>J Clin Virol</source><year>2005</year><volume>33</volume><issue>4</issue><fpage>341</fpage><lpage>344</lpage><?supplied-pmid 15927526?><pub-id pub-id-type="pmid">15927526</pub-id></element-citation></ref><ref id="CR108_21"><label>108.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Legoff</surname><given-names>J</given-names></name><etal/></person-group><article-title>Evaluation of the one-step multiplex real-time reverse transcription-PCR ProFlu-1 assay for detection of influenza A and influenza B viruses and respiratory syncytial viruses in children</article-title><source>J Clin Microbiol</source><year>2008</year><volume>46</volume><issue>2</issue><fpage>789</fpage><lpage>791</lpage><?supplied-pmid 18057126?><pub-id pub-id-type="pmid">18057126</pub-id></element-citation></ref><ref id="CR109_21"><label>109.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Markoulatos</surname><given-names>P</given-names></name><name><surname>Siafakas</surname><given-names>N</given-names></name><name><surname>Moncany</surname><given-names>M</given-names></name></person-group><article-title>Multiplex polymerase chain reaction: a practical approach</article-title><source>J Clin Lab Anal</source><year>2002</year><volume>16</volume><issue>1</issue><fpage>47</fpage><lpage>51</lpage><?supplied-pmid 11835531?><pub-id pub-id-type="pmid">11835531</pub-id></element-citation></ref><ref id="CR110_21"><label>110.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Templeton</surname><given-names>KE</given-names></name><etal/></person-group><article-title>Rapid and sensitive method using multiplex real-time PCR for diagnosis of infections by influenza a and influenza B viruses, respiratory syncytial virus, and parainfluenza viruses 1, 2, 3, and 4</article-title><source>J Clin Microbiol</source><year>2004</year><volume>42</volume><issue>4</issue><fpage>1564</fpage><lpage>1569</lpage><?supplied-pmid 15071005?><pub-id pub-id-type="pmid">15071005</pub-id></element-citation></ref><ref id="CR111_21"><label>111.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grondahl</surname><given-names>B</given-names></name><etal/></person-group><article-title>Rapid identification of nine microorganisms causing acute respiratory tract infections by single-tube multiplex reverse transcription-PCR: feasibility study</article-title><source>J Clin Microbiol</source><year>1999</year><volume>37</volume><issue>1</issue><fpage>1</fpage><lpage>7</lpage><?supplied-pmid 9854054?><pub-id pub-id-type="pmid">9854054</pub-id></element-citation></ref><ref id="CR112_21"><label>112.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Legoff</surname><given-names>J</given-names></name><etal/></person-group><article-title>High prevalence of respiratory viral infections in patients hospitalized in an intensive care unit for acute respiratory infections as detected by nucleic acid-based assays</article-title><source>J Clin Microbiol</source><year>2005</year><volume>43</volume><issue>1</issue><fpage>455</fpage><lpage>457</lpage><?supplied-pmid 15635014?><pub-id pub-id-type="pmid">15635014</pub-id></element-citation></ref><ref id="CR113_21"><label>113.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liolios</surname><given-names>L</given-names></name><etal/></person-group><article-title>Comparison of a multiplex reverse transcription-PCR-enzyme hybridization assay with conventional viral culture and immunofluorescence techniques for the detection of seven viral respiratory pathogens</article-title><source>J Clin Microbiol</source><year>2001</year><volume>39</volume><issue>8</issue><fpage>2779</fpage><lpage>2783</lpage><?supplied-pmid 11473991?><pub-id pub-id-type="pmid">11473991</pub-id></element-citation></ref><ref id="CR114_21"><label>114.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cannon</surname><given-names>GA</given-names></name><etal/></person-group><article-title>A low density oligonucleotide microarray for the detection of viral and atypical bacterial respiratory pathogens</article-title><source>J Virol Methods</source><year>2010</year><volume>163</volume><issue>1</issue><fpage>17</fpage><lpage>24</lpage><?supplied-pmid 19638287?><pub-id pub-id-type="pmid">19638287</pub-id></element-citation></ref><ref id="CR115_21"><label>115.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>H</given-names></name><etal/></person-group><article-title>Simultaneous detection and high-throughput identification of a panel of RNA viruses causing respiratory tract infections</article-title><source>J Clin Microbiol</source><year>2007</year><volume>45</volume><issue>7</issue><fpage>2105</fpage><lpage>2109</lpage><?supplied-pmid 17507510?><pub-id pub-id-type="pmid">17507510</pub-id></element-citation></ref><ref id="CR116_21"><label>116.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pabbaraju</surname><given-names>K</given-names></name><etal/></person-group><article-title>Comparison of the Luminex xTAG respiratory viral panel with in-house nucleic acid amplification tests for diagnosis of respiratory virus infections</article-title><source>J Clin Microbiol</source><year>2008</year><volume>46</volume><issue>9</issue><fpage>3056</fpage><lpage>3062</lpage><?supplied-pmid 18632902?><pub-id pub-id-type="pmid">18632902</pub-id></element-citation></ref><ref id="CR117_21"><label>117.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dominguez</surname><given-names>SR</given-names></name><etal/></person-group><article-title>Multiplex MassTag-PCR for respiratory pathogens in pediatric nasopharyngeal washes negative by conventional diagnostic testing shows a high prevalence of viruses belonging to a newly recognized rhinovirus clade</article-title><source>J Clin Virol</source><year>2008</year><volume>43</volume><issue>2</issue><fpage>219</fpage><lpage>222</lpage><?supplied-pmid 18674964?><pub-id pub-id-type="pmid">18674964</pub-id></element-citation></ref><ref id="CR118_21"><label>118.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reijans</surname><given-names>M</given-names></name><etal/></person-group><article-title>RespiFinder: a new multiparameter test to differentially identify fifteen respiratory viruses</article-title><source>J Clin Microbiol</source><year>2008</year><volume>46</volume><issue>4</issue><fpage>1232</fpage><lpage>1240</lpage><?supplied-pmid 18256230?><pub-id pub-id-type="pmid">18256230</pub-id></element-citation></ref><ref id="CR119_21"><label>119.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sampath</surname><given-names>R</given-names></name><etal/></person-group><article-title>Global surveillance of emerging Influenza virus genotypes by mass spectrometry</article-title><source>PLoS ONE</source><year>2007</year><volume>2</volume><issue>5</issue><fpage>e489</fpage><?supplied-pmid 17534439?><pub-id pub-id-type="pmid">17534439</pub-id></element-citation></ref><ref id="CR120_21"><label>120.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kuypers</surname><given-names>J</given-names></name><etal/></person-group><article-title>Comparison of conventional and molecular detection of respiratory viruses in hematopoietic cell transplant recipients</article-title><source>Transpl Infect Dis</source><year>2009</year><volume>11</volume><issue>4</issue><fpage>298</fpage><lpage>303</lpage><?supplied-pmid 19453994?><pub-id pub-id-type="pmid">19453994</pub-id></element-citation></ref><ref id="CR121_21"><label>121.</label><mixed-citation publication-type="other">Jefferson TO et al (2002) Amantadine and rimantadine for preventing and treating influenza A in adults. Cochrane Database Syst Rev (3):CD001169</mixed-citation></ref><ref id="CR122_21"><label>122.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bright</surname><given-names>RA</given-names></name><etal/></person-group><article-title>Adamantane resistance among influenza A viruses isolated early during the 2005-2006 influenza season in the United States</article-title><source>JAMA</source><year>2006</year><volume>295</volume><issue>8</issue><fpage>891</fpage><lpage>894</lpage><?supplied-pmid 16456087?><pub-id pub-id-type="pmid">16456087</pub-id></element-citation></ref><ref id="CR123_21"><label>123.</label><element-citation publication-type="journal"><person-group person-group-type="author"><collab>The MIST (Management of Influenza in the Southern Hemisphere Trialists) Study Group</collab></person-group><article-title>Randomised trial of efficacy and safety of inhaled zanamivir in treatment of influenza A and B virus infections</article-title><source>Lancet</source><year>1998</year><volume>352</volume><issue>9144</issue><fpage>1877</fpage><lpage>1881</lpage><pub-id pub-id-type="pmid">9863784</pub-id></element-citation></ref><ref id="CR124_21"><label>124.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nicholson</surname><given-names>KG</given-names></name><etal/></person-group><article-title>Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial. Neuraminidase Inhibitor Flu Treatment Investigator Group</article-title><source>Lancet</source><year>2000</year><volume>355</volume><issue>9218</issue><fpage>1845</fpage><lpage>1850</lpage><?supplied-pmid 10866439?><pub-id pub-id-type="pmid">10866439</pub-id></element-citation></ref><ref id="CR125_21"><label>125.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Treanor</surname><given-names>JJ</given-names></name><etal/></person-group><article-title>Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomised controlled trial. US Oral Neuraminidase Study Group</article-title><source>JAMA</source><year>2000</year><volume>283</volume><issue>8</issue><fpage>1016</fpage><lpage>1024</lpage><?supplied-pmid 10697061?><pub-id pub-id-type="pmid">10697061</pub-id></element-citation></ref><ref id="CR126_21"><label>126.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Monto</surname><given-names>AS</given-names></name><name><surname>Webster</surname><given-names>A</given-names></name><name><surname>Keene</surname><given-names>O</given-names></name></person-group><article-title>Randomized, placebo-controlled studies of inhaled zanamivir in the treatment of influenza A and B: pooled efficacy analysis</article-title><source>J Antimicrob Chemother</source><year>1999</year><volume>44</volume><issue>Suppl B</issue><fpage>23</fpage><lpage>29</lpage><?supplied-pmid 10877459?><pub-id pub-id-type="pmid">10877459</pub-id></element-citation></ref><ref id="CR127_21"><label>127.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aoki</surname><given-names>FY</given-names></name><etal/></person-group><article-title>Early administration of oral oseltamivir increases the benefits of influenza treatment</article-title><source>J Antimicrob Chemother</source><year>2003</year><volume>51</volume><issue>1</issue><fpage>123</fpage><lpage>129</lpage><?supplied-pmid 12493796?><pub-id pub-id-type="pmid">12493796</pub-id></element-citation></ref><ref id="CR128_21"><label>128.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McGeer</surname><given-names>A</given-names></name><etal/></person-group><article-title>Antiviral therapy and outcomes of influenza requiring hospitalization in Ontario, Canada</article-title><source>Clin Infect Dis</source><year>2007</year><volume>45</volume><issue>12</issue><fpage>1568</fpage><lpage>1575</lpage><?supplied-pmid 18190317?><pub-id pub-id-type="pmid">18190317</pub-id></element-citation></ref><ref id="CR129_21"><label>129.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hauge</surname><given-names>SH</given-names></name><etal/></person-group><article-title>Oseltamivir-resistant influenza viruses A (H1N1), Norway, 2007-08</article-title><source>Emerg Infect Dis</source><year>2009</year><volume>15</volume><issue>2</issue><fpage>155</fpage><lpage>162</lpage><?supplied-pmid 19193257?><pub-id pub-id-type="pmid">19193257</pub-id></element-citation></ref><ref id="CR130_21"><label>130.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Poland</surname><given-names>GA</given-names></name><name><surname>Jacobson</surname><given-names>RM</given-names></name><name><surname>Ovsyannikova</surname><given-names>IG</given-names></name></person-group><article-title>Influenza virus resistance to antiviral agents: a plea for rational use</article-title><source>Clin Infect Dis</source><year>2009</year><volume>48</volume><issue>9</issue><fpage>1254</fpage><lpage>1256</lpage><?supplied-pmid 19323631?><pub-id pub-id-type="pmid">19323631</pub-id></element-citation></ref><ref id="CR131_21"><label>131.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Machado</surname><given-names>CM</given-names></name><etal/></person-group><article-title>Use of Oseltamivir to control influenza complications after bone marrow transplantation</article-title><source>Bone Marrow Transplant</source><year>2004</year><volume>34</volume><issue>2</issue><fpage>111</fpage><lpage>114</lpage><?supplied-pmid 15094755?><pub-id pub-id-type="pmid">15094755</pub-id></element-citation></ref><ref id="CR132_21"><label>132.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Whimbey</surname><given-names>E</given-names></name><etal/></person-group><article-title>Combination therapy with aerosolized ribavirin and intravenous immunoglobulin for respiratory syncytial virus disease in adult bone marrow transplant recipients</article-title><source>Bone Marrow Transplant</source><year>1995</year><volume>16</volume><issue>3</issue><fpage>393</fpage><lpage>399</lpage><?supplied-pmid 8535312?><pub-id pub-id-type="pmid">8535312</pub-id></element-citation></ref><ref id="CR133_21"><label>133.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boeckh</surname><given-names>M</given-names></name><etal/></person-group><article-title>Randomized controlled multicenter trial of aerosolized ribavirin for respiratory syncytial virus upper respiratory tract infection in hematopoietic cell transplant recipients</article-title><source>Clin Infect Dis</source><year>2007</year><volume>44</volume><issue>2</issue><fpage>245</fpage><lpage>249</lpage><?supplied-pmid 17173225?><pub-id pub-id-type="pmid">17173225</pub-id></element-citation></ref><ref id="CR134_21"><label>134.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ghosh</surname><given-names>S</given-names></name><etal/></person-group><article-title>Respiratory syncytial virus infections in autologous blood and marrow transplant recipients with breast cancer: combination therapy with aerosolized ribavirin and parenteral immunoglobulins</article-title><source>Bone Marrow Transplant</source><year>2001</year><volume>28</volume><issue>3</issue><fpage>271</fpage><lpage>275</lpage><?supplied-pmid 11535995?><pub-id pub-id-type="pmid">11535995</pub-id></element-citation></ref><ref id="CR135_21"><label>135.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lewinsohn</surname><given-names>DM</given-names></name><etal/></person-group><article-title>Phase I study of intravenous ribavirin treatment of respiratory syncytial virus pneumonia after marrow transplantation</article-title><source>Antimicrob Agents Chemother</source><year>1996</year><volume>40</volume><issue>11</issue><fpage>2555</fpage><lpage>2557</lpage><?supplied-pmid 8913463?><pub-id pub-id-type="pmid">8913463</pub-id></element-citation></ref><ref id="CR136_21"><label>136.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>DeVincenzo</surname><given-names>JP</given-names></name><etal/></person-group><article-title>Respiratory syncytial virus immune globulin treatment of lower respiratory tract infection in pediatric patients undergoing bone marrow transplantation - a compassionate use experience</article-title><source>Bone Marrow Transplant</source><year>2000</year><volume>25</volume><issue>2</issue><fpage>161</fpage><lpage>165</lpage><?supplied-pmid 10673674?><pub-id pub-id-type="pmid">10673674</pub-id></element-citation></ref><ref id="CR137_21"><label>137.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ghosh</surname><given-names>S</given-names></name><etal/></person-group><article-title>Respiratory syncytial virus upper respiratory tract illnesses in adult blood and marrow transplant recipients: combination therapy with aerosolized ribavirin and intravenous immunoglobulin</article-title><source>Bone Marrow Transplant</source><year>2000</year><volume>25</volume><issue>7</issue><fpage>751</fpage><lpage>755</lpage><?supplied-pmid 10745261?><pub-id pub-id-type="pmid">10745261</pub-id></element-citation></ref><ref id="CR138_21"><label>138.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boeckh</surname><given-names>M</given-names></name><etal/></person-group><article-title>Phase 1 evaluation of the respiratory syncytial virus-specific monoclonal antibody palivizumab in recipients of hematopoietic stem cell transplants</article-title><source>J Infect Dis</source><year>2001</year><volume>184</volume><issue>3</issue><fpage>350</fpage><lpage>354</lpage><?supplied-pmid 11443562?><pub-id pub-id-type="pmid">11443562</pub-id></element-citation></ref><ref id="CR139_21"><label>139.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nichols</surname><given-names>WG</given-names></name><etal/></person-group><article-title>Parainfluenza virus infections after hematopoietic stem cell transplantation: risk factors, response to antiviral therapy, and effect on transplant outcome</article-title><source>Blood</source><year>2001</year><volume>98</volume><issue>3</issue><fpage>573</fpage><lpage>578</lpage><?supplied-pmid 11468152?><pub-id pub-id-type="pmid">11468152</pub-id></element-citation></ref><ref id="CR140_21"><label>140.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chakrabarti</surname><given-names>S</given-names></name><etal/></person-group><article-title>Parainfluenza virus type 3 infections in hematopoetic stem cell transplant recipients: response to ribavirin therapy</article-title><source>Clin Infect Dis</source><year>2000</year><volume>31</volume><issue>6</issue><fpage>1516</fpage><lpage>1518</lpage><?supplied-pmid 11096028?><pub-id pub-id-type="pmid">11096028</pub-id></element-citation></ref><ref id="CR141_21"><label>141.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wyde</surname><given-names>PR</given-names></name><etal/></person-group><article-title>Comparison of the inhibition of human metapneumovirus and respiratory syncytial virus by ribavirin and immune serum globulin in vitro</article-title><source>Antiviral Res</source><year>2003</year><volume>60</volume><issue>1</issue><fpage>51</fpage><lpage>59</lpage><?supplied-pmid 14516921?><pub-id pub-id-type="pmid">14516921</pub-id></element-citation></ref><ref id="CR142_21"><label>142.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bordigoni</surname><given-names>P</given-names></name><etal/></person-group><article-title>Treatment of adenovirus infections in patients undergoing allogeneic hematopoietic stem cell transplantation</article-title><source>Clin Infect Dis</source><year>2001</year><volume>32</volume><issue>9</issue><fpage>1290</fpage><lpage>1297</lpage><?supplied-pmid 11303263?><pub-id pub-id-type="pmid">11303263</pub-id></element-citation></ref><ref id="CR143_21"><label>143.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chakrabarti</surname><given-names>S</given-names></name><etal/></person-group><article-title>Fulminant adenovirus hepatitis following unrelated bone marrow transplantation: failure of intravenous ribavirin therapy</article-title><source>Bone Marrow Transplant</source><year>1999</year><volume>23</volume><issue>11</issue><fpage>1209</fpage><lpage>1211</lpage><?supplied-pmid 10382964?><pub-id pub-id-type="pmid">10382964</pub-id></element-citation></ref><ref id="CR144_21"><label>144.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gavin</surname><given-names>PJ</given-names></name><name><surname>Katz</surname><given-names>BZ</given-names></name></person-group><article-title>Intravenous ribavirin treatment for severe adenovirus disease in immunocompromised children</article-title><source>Pediatrics</source><year>2002</year><volume>110</volume><issue>1 Pt 1</issue><fpage>e9</fpage><?supplied-pmid 12093990?><pub-id pub-id-type="pmid">12093990</pub-id></element-citation></ref><ref id="CR145_21"><label>145.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liles</surname><given-names>WC</given-names></name><etal/></person-group><article-title>Severe adenoviral nephritis following bone marrow transplantation: successful treatment with intravenous ribavirin</article-title><source>Bone Marrow Transplant</source><year>1993</year><volume>12</volume><issue>4</issue><fpage>409</fpage><lpage>412</lpage><?supplied-pmid 8275042?><pub-id pub-id-type="pmid">8275042</pub-id></element-citation></ref><ref id="CR146_21"><label>146.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mann</surname><given-names>D</given-names></name><etal/></person-group><article-title>Failure of intravenous ribavirin in the treatment of invasive adenovirus infection following allogeneic bone marrow transplantation: a case report</article-title><source>J Infect</source><year>1998</year><volume>36</volume><issue>2</issue><fpage>227</fpage><lpage>228</lpage><?supplied-pmid 9570662?><pub-id pub-id-type="pmid">9570662</pub-id></element-citation></ref><ref id="CR147_21"><label>147.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miyamura</surname><given-names>K</given-names></name><etal/></person-group><article-title>Successful ribavirin therapy for severe adenovirus hemorrhagic cystitis after allogeneic marrow transplant from close HLA donors rather than distant donors</article-title><source>Bone Marrow Transplant</source><year>2000</year><volume>25</volume><issue>5</issue><fpage>545</fpage><lpage>548</lpage><?supplied-pmid 10713633?><pub-id pub-id-type="pmid">10713633</pub-id></element-citation></ref><ref id="CR148_21"><label>148.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hoffman</surname><given-names>JA</given-names></name><etal/></person-group><article-title>Adenoviral infections and a prospective trial of cidofovir in pediatric hematopoietic stem cell transplantation</article-title><source>Biol Blood Marrow Transplant</source><year>2001</year><volume>7</volume><issue>7</issue><fpage>388</fpage><lpage>394</lpage><?supplied-pmid 11529489?><pub-id pub-id-type="pmid">11529489</pub-id></element-citation></ref><ref id="CR149_21"><label>149.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Legrand</surname><given-names>F</given-names></name><etal/></person-group><article-title>Early diagnosis of adenovirus infection and treatment with cidofovir after bone marrow transplantation in children</article-title><source>Bone Marrow Transplant</source><year>2001</year><volume>27</volume><issue>6</issue><fpage>621</fpage><lpage>626</lpage><?supplied-pmid 11319592?><pub-id pub-id-type="pmid">11319592</pub-id></element-citation></ref><ref id="CR150_21"><label>150.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ljungman</surname><given-names>P</given-names></name><etal/></person-group><article-title>Cidofovir for adenovirus infections after allogeneic hematopoietic stem cell transplantation: a survey by the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation</article-title><source>Bone Marrow Transplant</source><year>2003</year><volume>31</volume><issue>6</issue><fpage>481</fpage><lpage>486</lpage><?supplied-pmid 12665844?><pub-id pub-id-type="pmid">12665844</pub-id></element-citation></ref><ref id="CR151_21"><label>151.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Neofytos</surname><given-names>D</given-names></name><etal/></person-group><article-title>Treatment of adenovirus disease in stem cell transplant recipients with cidofovir</article-title><source>Biol Blood Marrow Transplant</source><year>2007</year><volume>13</volume><issue>1</issue><fpage>74</fpage><lpage>81</lpage><?supplied-pmid 17222755?><pub-id pub-id-type="pmid">17222755</pub-id></element-citation></ref><ref id="CR152_21"><label>152.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sivaprakasam</surname><given-names>P</given-names></name><etal/></person-group><article-title>Improved outcome from invasive adenovirus infection in pediatric patients after hemopoietic stem cell transplantation using intensive clinical surveillance and early intervention</article-title><source>J Pediatr Hematol Oncol</source><year>2007</year><volume>29</volume><issue>2</issue><fpage>81</fpage><lpage>85</lpage><?supplied-pmid 17279003?><pub-id pub-id-type="pmid">17279003</pub-id></element-citation></ref><ref id="CR153_21"><label>153.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yusuf</surname><given-names>U</given-names></name><etal/></person-group><article-title>Cidofovir for the treatment of adenoviral infection in pediatric hematopoietic stem cell transplant patients</article-title><source>Transplantation</source><year>2006</year><volume>81</volume><issue>10</issue><fpage>1398</fpage><lpage>1404</lpage><?supplied-pmid 16732176?><pub-id pub-id-type="pmid">16732176</pub-id></element-citation></ref><ref id="CR154_21"><label>154.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Naesens</surname><given-names>L</given-names></name><etal/></person-group><article-title>Antiadenovirus activities of several classes of nucleoside and nucleotide analogues</article-title><source>Antimicrob Agents Chemother</source><year>2005</year><volume>49</volume><issue>3</issue><fpage>1010</fpage><lpage>1016</lpage><?supplied-pmid 15728896?><pub-id pub-id-type="pmid">15728896</pub-id></element-citation></ref><ref id="CR155_21"><label>155.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chakrabarti</surname><given-names>S</given-names></name><etal/></person-group><article-title>Adenovirus infections following haematopoietic cell transplantation: is there a role for adoptive immunotherapy?</article-title><source>Bone Marrow Transplant</source><year>2000</year><volume>26</volume><issue>3</issue><fpage>305</fpage><lpage>307</lpage><?supplied-pmid 10967570?><pub-id pub-id-type="pmid">10967570</pub-id></element-citation></ref><ref id="CR156_21"><label>156.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Feuchtinger</surname><given-names>T</given-names></name><etal/></person-group><article-title>Safe adoptive transfer of virus-specific T-cell immunity for the treatment of systemic adenovirus infection after allogeneic stem cell transplantation</article-title><source>Br J Haematol</source><year>2006</year><volume>134</volume><issue>1</issue><fpage>64</fpage><lpage>76</lpage><?supplied-pmid 16803570?><pub-id pub-id-type="pmid">16803570</pub-id></element-citation></ref><ref id="CR157_21"><label>157.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Teramura</surname><given-names>T</given-names></name><etal/></person-group><article-title>Quantitative detection of serum adenovirus in a transplant recipient</article-title><source>Lancet</source><year>2002</year><volume>359</volume><issue>9321</issue><fpage>1945</fpage><?supplied-pmid 12057576?><pub-id pub-id-type="pmid">12057576</pub-id></element-citation></ref><ref id="CR158_21"><label>158.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cortez</surname><given-names>KJ</given-names></name><etal/></person-group><article-title>Outbreak of human parainfluenza virus 3 infections in a hematopoietic stem cell transplant population</article-title><source>J Infect Dis</source><year>2001</year><volume>184</volume><issue>9</issue><fpage>1093</fpage><lpage>1097</lpage><?supplied-pmid 11598830?><pub-id pub-id-type="pmid">11598830</pub-id></element-citation></ref><ref id="CR159_21"><label>159.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>S</given-names></name><etal/></person-group><article-title>Molecular epidemiological investigation of a nosocomial outbreak of human metapneumovirus infection in a pediatric hemato-oncology patient population</article-title><source>J Clin Microbiol</source><year>2009</year><volume>47</volume><issue>4</issue><fpage>1221</fpage><lpage>1224</lpage><?supplied-pmid 19213698?><pub-id pub-id-type="pmid">19213698</pub-id></element-citation></ref><ref id="CR160_21"><label>160.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nichols</surname><given-names>WG</given-names></name><etal/></person-group><article-title>Prolonged outbreak of human parainfluenza virus 3 infection in a stem cell transplant outpatient department: insights from molecular epidemiologic analysis</article-title><source>Biol Blood Marrow Transplant</source><year>2004</year><volume>10</volume><issue>1</issue><fpage>58</fpage><lpage>64</lpage><?supplied-pmid 14752780?><pub-id pub-id-type="pmid">14752780</pub-id></element-citation></ref><ref id="CR161_21"><label>161.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Daugherty</surname><given-names>EL</given-names></name><etal/></person-group><article-title>The use of personal protective equipment for control of influenza among critical care clinicians: A survey study</article-title><source>Crit Care Med</source><year>2009</year><volume>37</volume><issue>4</issue><fpage>1210</fpage><lpage>1216</lpage><?supplied-pmid 19242326?><pub-id pub-id-type="pmid">19242326</pub-id></element-citation></ref><ref id="CR162_21"><label>162.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Siegel</surname><given-names>JD</given-names></name><etal/></person-group><article-title>2007 Guideline for Isolation Precautions: Preventing Transmission of Infectious Agents in Health Care Settings</article-title><source>Am J Infect Control</source><year>2007</year><volume>35</volume><issue>10 Suppl 2</issue><fpage>S65</fpage><lpage>S164</lpage><?supplied-pmid 18068815?><pub-id pub-id-type="pmid">18068815</pub-id></element-citation></ref><ref id="CR163_21"><label>163.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blachere</surname><given-names>FM</given-names></name><etal/></person-group><article-title>Measurement of airborne influenza virus in a hospital emergency department</article-title><source>Clin Infect Dis</source><year>2009</year><volume>48</volume><issue>4</issue><fpage>438</fpage><lpage>440</lpage><?supplied-pmid 19133798?><pub-id pub-id-type="pmid">19133798</pub-id></element-citation></ref><ref id="CR164_21"><label>164.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bridges</surname><given-names>CB</given-names></name><name><surname>Kuehnert</surname><given-names>MJ</given-names></name><name><surname>Hall</surname><given-names>CB</given-names></name></person-group><article-title>Transmission of influenza: implications for control in health care settings</article-title><source>Clin Infect Dis</source><year>2003</year><volume>37</volume><issue>8</issue><fpage>1094</fpage><lpage>1101</lpage><?supplied-pmid 14523774?><pub-id pub-id-type="pmid">14523774</pub-id></element-citation></ref><ref id="CR165_21"><label>165.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Johnson</surname><given-names>DF</given-names></name><etal/></person-group><article-title>A quantitative assessment of the efficacy of surgical and N95 masks to filter influenza virus in patients with acute influenza infection</article-title><source>Clin Infect Dis</source><year>2009</year><volume>49</volume><issue>2</issue><fpage>275</fpage><lpage>277</lpage><?supplied-pmid 19522650?><pub-id pub-id-type="pmid">19522650</pub-id></element-citation></ref><ref id="CR166_21"><label>166.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Loeb</surname><given-names>M</given-names></name><etal/></person-group><article-title>Surgical mask vs N95 respirator for preventing influenza among health care workers: a randomized trial</article-title><source>JAMA</source><year>2009</year><volume>302</volume><fpage>1865</fpage><lpage>1871</lpage><pub-id pub-id-type="pmid">19797474</pub-id></element-citation></ref><ref id="CR167_21"><label>167.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brydak</surname><given-names>LB</given-names></name><etal/></person-group><article-title>Humoral response to hemagglutinin components of influenza vaccine in patients with non-Hodgkin malignant lymphoma</article-title><source>Vaccine</source><year>2006</year><volume>24</volume><issue>44&#x02013;46</issue><fpage>6620</fpage><lpage>6623</lpage><?supplied-pmid 16870313?><pub-id pub-id-type="pmid">16870313</pub-id></element-citation></ref><ref id="CR168_21"><label>168.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Engelhard</surname><given-names>D</given-names></name><etal/></person-group><article-title>Antibody response to a two-dose regimen of influenza vaccine in allogeneic T cell-depleted and autologous BMT recipients</article-title><source>Bone Marrow Transplant</source><year>1993</year><volume>11</volume><issue>1</issue><fpage>1</fpage><lpage>5</lpage><?supplied-pmid 8431706?><pub-id pub-id-type="pmid">8431706</pub-id></element-citation></ref><ref id="CR169_21"><label>169.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ljungman</surname><given-names>P</given-names></name><name><surname>Nahi</surname><given-names>H</given-names></name><name><surname>Linde</surname><given-names>A</given-names></name></person-group><article-title>Vaccination of patients with haematological malignancies with one or two doses of influenza vaccine: a randomised study</article-title><source>Br J Haematol</source><year>2005</year><volume>130</volume><issue>1</issue><fpage>96</fpage><lpage>98</lpage><?supplied-pmid 15982350?><pub-id pub-id-type="pmid">15982350</pub-id></element-citation></ref><ref id="CR170_21"><label>170.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lo</surname><given-names>W</given-names></name><etal/></person-group><article-title>Antibody response to a two-dose influenza vaccine regimen in adult lymphoma patients on chemotherapy</article-title><source>Eur J Clin Microbiol Infect Dis</source><year>1993</year><volume>12</volume><issue>10</issue><fpage>778</fpage><lpage>782</lpage><?supplied-pmid 8307050?><pub-id pub-id-type="pmid">8307050</pub-id></element-citation></ref><ref id="CR171_21"><label>171.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ortbals</surname><given-names>DW</given-names></name><etal/></person-group><article-title>Influenza immunization of adult patients with malignant diseases</article-title><source>Ann Intern Med</source><year>1977</year><volume>87</volume><issue>5</issue><fpage>552</fpage><lpage>557</lpage><?supplied-pmid 921082?><pub-id pub-id-type="pmid">921082</pub-id></element-citation></ref><ref id="CR172_21"><label>172.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pauksen</surname><given-names>K</given-names></name><etal/></person-group><article-title>Granulocyte-macrophage colony-stimulating factor as immunomodulating factor together with influenza vaccination in stem cell transplant patients</article-title><source>Clin Infect Dis</source><year>2000</year><volume>30</volume><issue>2</issue><fpage>342</fpage><lpage>348</lpage><?supplied-pmid 10671339?><pub-id pub-id-type="pmid">10671339</pub-id></element-citation></ref><ref id="CR173_21"><label>173.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Machado</surname><given-names>CM</given-names></name><etal/></person-group><article-title>The benefit of influenza vaccination after bone marrow transplantation</article-title><source>Bone Marrow Transplant</source><year>2005</year><volume>36</volume><issue>10</issue><fpage>897</fpage><lpage>900</lpage><?supplied-pmid 16170332?><pub-id pub-id-type="pmid">16170332</pub-id></element-citation></ref><ref id="CR174_21"><label>174.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ljungman</surname><given-names>P</given-names></name><etal/></person-group><article-title>Vaccination of stem cell transplant recipients: recommendations of the Infectious Diseases Working Party of the EBMT</article-title><source>Bone Marrow Transplant</source><year>2005</year><volume>35</volume><issue>8</issue><fpage>737</fpage><lpage>746</lpage><?supplied-pmid 15750612?><pub-id pub-id-type="pmid">15750612</pub-id></element-citation></ref><ref id="CR175_21"><label>175.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Salgado</surname><given-names>CD</given-names></name><etal/></person-group><article-title>Preventing nosocomial influenza by improving the vaccine acceptance rate of clinicians</article-title><source>Infect Control Hosp Epidemiol</source><year>2004</year><volume>25</volume><issue>11</issue><fpage>923</fpage><lpage>928</lpage><?supplied-pmid 15566025?><pub-id pub-id-type="pmid">15566025</pub-id></element-citation></ref><ref id="CR176_21"><label>176.</label><element-citation publication-type="journal"><person-group person-group-type="author"><collab>Groupe de Travail</collab></person-group><article-title>Taking care of influenza in the context of a pandemic in 2005. Full text</article-title><source>Med Mal Infect</source><year>2005</year><volume>35</volume><issue>Suppl 4</issue><fpage>S245</fpage><lpage>273</lpage><pub-id pub-id-type="pmid">16535783</pub-id></element-citation></ref><ref id="CR177_21"><label>177.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vu</surname><given-names>D</given-names></name><etal/></person-group><article-title>Safety and tolerability of oseltamivir prophylaxis in hematopoietic stem cell transplant recipients: a retrospective case-control study</article-title><source>Clin Infect Dis</source><year>2007</year><volume>45</volume><issue>2</issue><fpage>187</fpage><lpage>193</lpage><?supplied-pmid 17578777?><pub-id pub-id-type="pmid">17578777</pub-id></element-citation></ref><ref id="CR178_21"><label>178.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peck</surname><given-names>AJ</given-names></name><name><surname>Corey</surname><given-names>L</given-names></name><name><surname>Boeckh</surname><given-names>M</given-names></name></person-group><article-title>Pretransplantation respiratory syncytial virus infection: impact of a strategy to delay transplantation</article-title><source>Clin Infect Dis</source><year>2004</year><volume>39</volume><issue>5</issue><fpage>673</fpage><lpage>680</lpage><?supplied-pmid 15356782?><pub-id pub-id-type="pmid">15356782</pub-id></element-citation></ref></ref-list></back></article>